KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention,
and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
3
Tables and supplementary material
6
KDIGO Executive Committee
7
Reference keys
8
CKD nomenclature
9
Conversion factors
10
Abbreviations and acronyms
11
Notice
12
Foreword
13
Work Group membership
14
Abstract
15
Summary of KDIGO CKD-MBD recommendations
19
Summary and comparison of 2017 updated and 2009 KDIGO CKD-MBD recommendations
22
Chapter 3.2: Diagnosis of CKD-MBD: bone
25
Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphate and maintaining
serum calcium
33
Chapter 4.2: Treatment of abnormal PTH levels in CKD-MBD
38
Chapter 4.3: Treatment of bone with bisphosphonates, other osteoporosis medications,
and growth hormone
39
Chapter 5: Evaluation and treatment of kidney transplant bone disease
41
Methodological approach to the 2017 KDIGO CKD-MBD guideline update
49
Biographic and disclosure information
55
Acknowledgments
56
References
Tables
24
Table 1. Utility of KDOQI and KDIGO PTH thresholds for diagnostic decision making
42
Table 2. Research questions
45
Table 3. Question-specific eligibility criteria
46
Table 4. GRADE system for grading quality of evidence for an outcome
47
Table 5. Final grade for overall quality of evidence
47
Table 6. Balance of benefits and harms
47
Table 7. Implications of the strength of a recommendation
47
Table 8. Determinants of strength of recommendation
Supplementary Material
Appendix A. PubMed search strategy
Appendix B. Summary of search and review process
Table S1. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with bisphosphonates in CKD G3a–G5: study characteristics
Table S2. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with bisphosphonates in CKD G3a–G5: study population characteristics
Table S3. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with bisphosphonates in CKD G3a–G5: results
Table S4. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with bisphosphonates in CKD G3a–G5: quality
Table S5. Evidence matrix of randomized controlled trials examining the treatment
of CKD-MBD with bisphosphonates in CKD G3a–G5
Table S6. Evidence profile of randomized controlled trials examining the treatment
of CKD-MBD with bisphosphonates in CKD G3a–G5
Table S7. Summary table of studies evaluating the ability of bone mineral density
results to predict fracture or renal osteodystrophy among patients with CKD G3a–G5:
study characteristics
Table S8. Summary table of studies evaluating the ability of bone mineral density
results to predict fracture or renal osteodystrophy among patients with CKD G3a–G5:
study population characteristics
Table S9. Summary table of studies evaluating the ability of bone mineral density
results to predict fracture or renal osteodystrophy among patients with CKD G3a–G5:
results
Table S10. Summary table of studies evaluating the ability of bone mineral density
results to predict fracture or renal osteodystrophy among patients with CKD G3a–G5:
quality
Table S11. Evidence matrix of studies evaluating the ability of bone mineral density
results to predict fracture or renal osteodystrophy among patients with CKD G3a–G5
Table S12. Evidence profile of studies evaluating the ability of bone mineral density
results to predict fracture or renal osteodystrophy among patients with CKD G3a–G5
Table S13. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with varying dialysate calcium concentration levels in CKD G5D: study characteristics
Table S14. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with varying dialysate calcium concentration levels in CKD G5D: study population
characteristics
Table S15. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with varying dialysate calcium concentration levels in CKD G5D: results
Table S16. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with varying dialysate calcium concentration levels in CKD G5D: quality
Table S17. Evidence matrix of randomized controlled trials examining the treatment
of CKD-MBD with varying dialysate calcium concentration levels in CKD G5D
Table S18. Evidence profile of randomized controlled trials examining the treatment
of CKD-MBD with varying dialysate calcium concentration levels in CKD G5D
Table S19. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with calcium-containing phosphate binders versus calcium-free phosphate binders:
study characteristics
Table S20. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with calcium-containing phosphate binders versus calcium-free phosphate binders:
study population characteristics
Table S21. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with calcium-containing phosphate binders versus calcium-free phosphate binders:
results
Table S22. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with calcium-containing phosphate binders versus calcium-free phosphate binders:
quality
Table S23. Evidence matrix of randomized controlled trials examining the treatment
of CKD-MBD with calcium-containing phosphate binders versus calcium-free phosphate
binders
Table S24. Evidence profile of randomized controlled trials examining the treatment
of CKD-MBD with calcium-containing phosphate binders versus calcium-free phosphate
binders
Table S25. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with dietary phosphate: study characteristics
Table S26. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with dietary phosphate: study population characteristics
Table S27. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with dietary phosphate: results
Table S28. Summary table of randomized controlled trials examining the treatment of
CKD-MBD with dietary phosphate: quality
Table S29. Evidence matrix of randomized controlled trials examining the treatment
of CKD-MBD with dietary phosphate
Table S30. Evidence profile of randomized controlled trials examining the treatment
of CKD-MBD with dietary phosphate
Table S31. Summary table of randomized controlled trials examining the treatment of
PTH in CKD-MBD: study characteristics
Table S32. Summary table of randomized controlled trials examining the treatment of
PTH in CKD-MBD: study population characteristics
Table S33. Summary table of randomized controlled trials examining the treatment of
PTH in CKD-MBD: results
Table S34. Summary table of randomized controlled trials examining the treatment of
PTH in CKD-MBD: quality
Table S35. Evidence matrix of randomized controlled trials examining the treatment
of PTH in CKD-MBD
Table S36. Evidence profile of randomized controlled trials examining the treatment
of PTH in CKD-MBD
Table S37. Summary table of randomized controlled trials examining the treatment of
high levels of PTH with calcitriol or activated vitamin D analogs in CKD G3a–G5 not
on dialysis: study characteristics
Table S38. Summary table of randomized controlled trials examining the treatment of
high levels of PTH with calcitriol or activated vitamin D analogs in CKD G3a–G5 not
on dialysis: study population characteristics
Table S39. Summary table of randomized controlled trials examining the treatment of
high levels of PTH with calcitriol or activated vitamin D analogs in CKD G3a–G5 not
on dialysis: results
Table S40. Summary table of randomized controlled trials examining the treatment of
high levels of PTH with calcitriol or activated vitamin D analogs in CKD G3a–G5 not
on dialysis: quality
Table S41. Evidence matrix of randomized controlled trials examining the treatment
of high levels of PTH with calcitriol or activated vitamin D analogs in CKD G3a–G5
not on dialysis
Table S42. Evidence profile of randomized controlled trials examining the treatment
of high levels of PTH with calcitriol or activated vitamin D analogs in CKD G3a–G5
not on dialysis
Table S43. Summary table of randomized controlled trials examining the treatment of
high levels of PTH in CKD G5D: study characteristics
Table S44. Summary table of randomized controlled trials examining the treatment of
high levels of PTH in CKD G5D: study population characteristics
Table S45. Summary table of randomized controlled trials examining the treatment of
high levels of PTH in CKD G5D: results
Table S46. Summary table of randomized controlled trials examining the treatment of
high levels of PTH in CKD G5D: quality
Table S47. Evidence matrix of randomized controlled trials examining the treatment
of high levels of PTH in CKD G5D
Table S48. Evidence profile of randomized controlled trials examining the treatment
of high levels of PTH in CKD G5D
Table S49. Summary table of studies evaluating different concentrations of serum phosphate
or calcium among patients with CKD G3a–G5 or G5D: study characteristics
Table S50. Summary table of studies evaluating different concentrations of serum phosphate
or calcium among patients with CKD G3a–G5 or G5D: study population characteristics
Table S51. Summary table of studies evaluating different concentrations of serum phosphate
among patients with CKD G3a–G5 or G5D: results
Table S52. Summary table of studies evaluating different concentrations of serum calcium
among patients with CKD G3a–G5 or G5D: results
Table S53. Summary table of studies evaluating different concentrations of serum phosphate
or calcium among patients with CKD G3a–G5 or G5D: quality
Table S54. Evidence matrix of studies evaluating different concentrations of serum
phosphate or calcium among patients with CKD G3a–G5 or G5D
Table S55. Evidence profile of studies evaluating different concentrations of serum
phosphate or calcium among patients with CKD G3a–G5 or G5D
Supplementary material is linked to the online version of the paper at www.kisupplements.org.
KDIGO Executive Committee
Garabed Eknoyan, MDNorbert Lameire, MD, PhDFounding KDIGO Co-chairs
Bertram L. Kasiske, MDImmediate Past Co-chair
David C. Wheeler, MD, FRCPKDIGO Co-chair
Wolfgang C. Winkelmayer, MD, MPH, ScDKDIGO Co-chair
Ali K. Abu-Alfa, MDOlivier Devuyst, MD, PhDJürgen Floege, MDJohn S. Gill, MD, MSKunitoshi
Iseki, MDAndrew S. Levey, MDZhi-Hong Liu, MD
Ziad A. Massy, MD, PhDRoberto Pecoits-Filho, MD, PhDBrian J.G. Pereira, MBBS, MD,
MBAPaul E. Stevens, MB, FRCPMarcello A. Tonelli, MD, SM, FRCPCAngela Yee-Moon Wang,
MD, PhD, FRCPAngela C. Webster, MBBS, MM (Clin Ep), PhD
KDIGO Staff
John Davis, Chief Executive OfficerDanielle Green, Managing DirectorMichael Cheung,
Chief Scientific OfficerTanya Green, Communications DirectorMelissa McMahan, Programs
Director
Reference keys
Nomenclature and Description for Rating Guideline Recommendations
Within each recommendation, the strength of recommendation is indicated as Level 1,
Level 2, or not graded, and the quality of the supporting evidence is shown as A,
B, C, or D.
Grade∗
Implications
Patients
Clinicians
Policy
Level 1
“We recommend”
Most people in your situation would want the recommended course of action, and only
a small proportion would not.
Most patients should receive the recommended course of action.
The recommendation can be evaluated as a candidate for developing a policy or a performance
measure.
Level 2
“We suggest”
The majority of people in your situation would want the recommended course of action,
but many would not.
Different choices will be appropriate for different patients. Each patient needs help
to arrive at a management decision consistent with her or his values and preferences.
The recommendation is likely to require substantial debate and involvement of stakeholders
before policy can be determined.
∗
The additional category “not graded” is used, typically, to provide guidance based
on common sense or when the topic does not allow adequate application of evidence.
The most common examples include recommendations regarding monitoring intervals, counseling,
and referral to other clinical specialists. The ungraded recommendations are generally
written as simple declarative statements, but are not meant to be interpreted as being
stronger recommendations than Level 1 or 2 recommendations.
Grade
Quality of evidence
Meaning
A
High
We are confident that the true effect lies close to that of the estimate of the effect.
B
Moderate
The true effect is likely to be close to the estimate of the effect, but there is
a possibility that it is substantially different.
C
Low
The true effect may be substantially different from the estimate of the effect.
D
Very low
The estimate of effect is very uncertain, and often will be far from the truth.
Current Chronic Kidney Disease (CKD) Nomenclature Used by KDIGO
CKD is defined as abnormalities of kidney structure or function, present for > 3 months,
with implications for health. CKD is classified based on cause, GFR category (G1–G5),
and albuminuria category (A1–A3), abbreviated as CGA.
Prognosis of CKD by GFR and albuminuria category
Conversion Factors of Conventional Units to SI Units
Conventional unit
Conversion factor
SI unit
Calcium, total
mg/dl
0.2495
mmol/l
Calcium, ionized
mg/dl
0.25
mmol/l
Creatinine
mg/dl
88.4
μmol/l
Parathyroid hormone
pg/ml
0.106
pmol/l
Phosphate (inorganic)
mg/dl
0.3229
mmol/l
Note: conventional unit × conversion factor = SI unit.
Abbreviations and acronyms
1,25(OH)2D
1,25-dihydroxyvitamin D
25(OH)D
25-hydroxyvitamin D
AUC
area under the curve
bALP
bone-specific alkaline phosphatase
BMD
bone mineral density
CAC
coronary artery calcification
CI
confidence interval
CT
computed tomography
CV
coefficient of variation
DXA
dual-energy X-ray absorptiometry
eGFR
estimated glomerular filtration rate
ERT
evidence review team
FGF
fibroblast growth factor
FRAX
fracture risk assessment tool
GFR
glomerular filtration rate
GI
gastrointestinal
GRADE
Grading of Recommendations Assessment, Development, and Evaluation
HD
hemodialysis
HPT
hyperparathyroidism
HR
hazard ratio
iPTH
intact parathyroid hormone
ISCD
International Society of Clinical Densitometry
ITT
intention-to-treat
IU
international unit
KDIGO
Kidney Disease: Improving Global Outcomes
KDOQI
Kidney Disease Outcomes Quality Initiative
LVH
left ventricular hypertrophy
LVMI
left ventricular mass index
MRI
magnetic resonance imaging
OR
odds ratio
P1NP
amino-terminal propeptide of type 1 procollagen
PTH
parathyroid hormone
RCT
randomized controlled trial
ROC
receiver operating characteristic
SD
standard deviation
SHPT
secondary hyperparathyroidism
VDR
vitamin D receptor
Notice
Section I: Use of the Clinical Practice Guideline
This Clinical Practice Guideline Update is based upon systematic literature searches
last conducted in September 2015 supplemented with additional evidence through February
2017. It is designed to assist decision making. It is not intended to define a standard
of care, and should not be interpreted as prescribing an exclusive course of management.
Variations in practice will inevitably and appropriately occur when clinicians consider
the needs of individual patients, available resources, and limitations unique to an
institution or type of practice. Health care professionals using these recommendations
should decide how to apply them to their own clinical practice.
Section II: Disclosure
Kidney Disease: Improving Global Outcomes (KDIGO) makes every effort to avoid any
actual or reasonably perceived conflicts of interest that may arise from an outside
relationship or a personal, professional, or business interest of a member of the
Work Group. All members of the Work Group are required to complete, sign, and submit
a disclosure and attestation form showing all such relationships that might be perceived
as or are actual conflicts of interest. This document is updated annually, and information
is adjusted accordingly. All reported information is published in its entirety at
the end of this document in the Work Group members’ Biographic and Disclosure section,
and is kept on file at KDIGO.
Copyright © 2017, KDIGO. Published by Elsevier on behalf of the International Society
of Nephrology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Single copies may be made for personal use as allowed by national copyright laws.
Special rates are available for educational institutions that wish to make photocopies
for nonprofit educational use. No part of this publication may be reproduced, amended,
or transmitted in any form or by any means, electronic or mechanical, including photocopying,
recording, or any information storage and retrieval system, without explicit permission
in writing from KDIGO. Details on how to seek permission for reproduction or translation,
and further information about KDIGO’s permissions policies can be obtained by contacting
Danielle Green, Managing Director, at danielle.green@kdigo.org.
To the fullest extent of the law, neither KDIGO, Kidney International Supplements,
nor the authors, contributors, or editors, assume any liability for any injury and/or
damage to persons or property as a matter of products liability, negligence or otherwise,
or from any use or operation of any methods, products, instructions, or ideas contained
in the material herein.
Foreword
With the growing awareness that chronic kidney disease is an international health
problem, Kidney Disease: Improving Global Outcomes (KDIGO) was established in 2003
with its stated mission to “improve the care and outcomes of kidney disease patients
worldwide through promoting coordination, collaboration, and integration of initiatives
to develop and implement clinical practice guidelines.”
When the KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention,
and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) was originally
published in 2009, the Work Group acknowledged the lack of high-quality evidence on
which to base recommendations. The Guideline included specific research recommendations
to encourage investigators to help fill the gaps and bolster the evidence base.
Multiple randomized controlled trials and prospective cohort studies have been published
since the 2009 Guideline, and therefore KDIGO recognizes the need to reexamine the
currency of all of its guidelines on a periodic basis. Accordingly, KDIGO convened
a Controversies Conference in 2013, titled “CKD-MBD: Back to the Future,” whose objective
was to determine whether sufficient new data had emerged to support a reassessment
of the 2009 CKD-MBD Clinical Practice Guideline and, if so, to determine the scope
of the potential revisions.
Although most of the recommendations were still considered to be current, the conference
identified a total of 12 recommendations for reevaluation based on new data. In addition,
the conference prepared a table of additional topic questions to be considered by
the guideline update Work Group. The conference noted that, in spite of the completion
of several key clinical trials since the 2009 publication of the CKD-MBD guideline,
large gaps of knowledge still remained, as demonstrated by the relatively small number
of recommendation statements identified for reevaluation. Interested readers should
refer to the conference publication for further details regarding its processes and
deliberations.
1
Therefore, KDIGO commissioned an update to the CKD-MBD guideline and formed a Work
Group, led by Drs. Markus Ketteler and Mary Leonard. The Work Group convened in June
2015 to review and appraise the evidence accumulated since the 2009 Guideline. The
topics addressed for revision are listed in Table 2 and included issues prompted by
EVOLVE post hoc analyses, which were published after the 2013 Controversies Conference.
Though 8 years have passed since the 2009 CKD-MBD guideline, evidence in many areas
is still lacking, which has resulted in many of the “opinion-based” recommendation
statements from the original guideline document remaining unchanged.
Table 2
Research questions
Section
2009 rec. no.
Research question
Key outcomes
Additional outcomes
Bone quality
3.2.1
In patients with CKD G3a–G5D, what is the effect on bone quality of bisphosphonates,
teriparatide, denosumab, and raloxifene?
•
TMV (as measured by bone biopsy)
•
BMD/bone mineral content
•
Fracture
4.3.4
In patients with CKD G4–G5D, what is the effect on bone quality of bisphosphonates,
teriparatide, denosumab, and raloxifene?
•
TMV (as measured by bone biopsy)
•
BMD/bone mineral content
•
Fracture
3.2.2
(a) In patients with CKD G3a–G5D, how well do BMD results predict fractures?(b) In
patients with CKD G3a–G5D, how well do BMD results predict renal osteodystrophy?
(a)
Fracture
(b)
TMV
5.5
In patients with CKD G1–G3b and transplant recipients, how well do BMD results predict
fractures?
•
Fracture
5.7
In patients with CKD G4–G5 and transplant recipients, how well do BMD results predict
fractures?
•
Fracture
Calcium and phosphate
4.1.1
In patients with G3a–G5 or G5D, what is the evidence for benefit or harm in maintaining
serum phosphate in the normal range compared with other targets of serum phosphate
in terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?
•
Mortality
•
GFR decline
•
Cardiovascular and cerebrovascular events
•
Phosphate
•
Bone histology, BMD
•
Vascular and valvular calcification imaging
•
Hospitalizations
•
Quality of life
•
Kidney or kidney graft failure
•
Fracture
•
Parathyroidectomy
•
Clinical adverse events
•
Growth, skeletal deformities, bone accrual
•
Calciphylaxis/CUA
4.1.3
In patients with CKD G5D, what is the evidence for benefit or harm in using a dialysate
calcium concentration between 1.25 and 1.50 mmol/l (2.5 and 3.0 mEq/l) compared with
other concentrations of dialysate calcium in terms of biochemical outcomes, other
surrogate outcomes, and patient-centered outcomes?
•
Mortality
•
Cardiovascular and cerebrovascular events
•
Calcium
•
Bone histology, BMD
•
Vascular and valvular calcification imaging
•
Measures of GFR
•
Hospitalizations
•
Quality of life
•
Kidney or kidney graft failure
•
Fracture
•
Parathyroidectomy
•
Clinical adverse events
•
Growth, skeletal deformities, bone accrual
•
Calciphylaxis/CUA
4.1.2
In patients with CKD G3a–G5D, what is the evidence for benefit or harm in maintaining
serum calcium in the normal range compared with other targets of serum calcium in
terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?
•
Mortality
•
Cardiovascular and cerebrovascular events
•
Calcium
•
Bone histology, BMD
•
Vascular and valvular calcification imaging
•
Measures of GFR
•
Hospitalizations
•
Quality of life
•
Kidney or kidney graft failure
•
Fracture
•
Parathyroidectomy
•
Clinical adverse events
•
Growth, skeletal deformities, bone accrual
•
Calciphylaxis/CUA
4.1.4
In patients with CKD G3a–G5 or G5D with hyperphosphatemia, what is the evidence for
benefit or harm in using calcium-containing phosphate-binding agents to treat hyperphosphatemia
compared with calcium-free phosphate-binding agents in terms of biochemical outcomes,
other surrogate outcomes, and patient-centered outcomes?
•
Mortality
•
Cardiovascular and cerebrovascular events
•
Phosphate
•
Bone histology, BMD
•
Vascular and valvular calcification imaging
•
Measures of GFR
•
Hospitalizations
•
Quality of life
•
Kidney or kidney graft failure
•
Fracture
•
Parathyroidectomy
•
Clinical adverse events
•
Growth, skeletal deformities, bone accrual
•
Calciphylaxis/CUA
4.1.7
In patients with CKD G3a–G5D with hyperphosphatemia, what is the evidence for benefit
or harm in limiting dietary phosphate intake compared with a standard diet in terms
of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?
•
Mortality
•
Cardiovascular and cerebrovascular events
•
Vascular and valvular calcification
•
Phosphate
•
Bone histology, BMD
•
Measures of GFR
•
Hospitalizations
•
Quality of life
•
Kidney or kidney graft failure
•
Fracture
•
Parathyroidectomy
•
Clinical adverse events
•
Growth, skeletal deformities, bone accrual
•
Calciphylaxis/CUA
Vitamin D and PTH
4.2.1
In patients with CKD G3a–G5 not on dialysis with levels of intact PTH above the upper
normal limit of the assay, what is the evidence for benefit or harm in reducing dietary
phosphate intake or treating with phosphate-binding agents, calcium supplements, or
native vitamin D in terms of biochemical outcomes, other surrogate outcomes, and patient-centered
outcomes?
•
Mortality
•
Cardiovascular and cerebrovascular events
•
GFR decline
•
Calcium
•
Phosphate
•
Parathyroid hormone
•
25-hydroxyvitamin D [25(OH)D]
•
1,25-dihydroxyvitamin D [1,25(OH)2D]
•
Alkaline phosphatases
•
Bone-specific alkaline phosphatase
•
Bicarbonate
•
FGF23
•
Bone histology, BMD
•
Vascular and valvular calcification imaging
•
Measures of GFR
•
Hospitalizations
•
Quality of life
•
Kidney or kidney graft failure
•
Fracture
•
Parathyroidectomy
•
Clinical adverse events
•
Growth, skeletal deformities, bone accrual
•
Calciphylaxis/CUA
4.2.2
In patients with CKD G3a–G5 not on dialysis, in whom serum PTH is progressively rising
and remains persistently above the upper limit of normal for the assay despite correction
of modifiable factors, what is the evidence for benefit or harm in treating with calcitriol
or vitamin D analogs compared with placebo or active control in terms of biochemical
outcomes, other surrogate outcomes, and patient-centered outcomes?
•
LVH
•
Hypercalcemia
•
Mortality
•
Cardiovascular and cerebrovascular events
•
Calcium
•
Phosphate
•
Parathyroid hormone
•
25-hydroxyvitamin D [25(OH)D]
•
1,25-dihydroxyvitamin D [1,25(OH)2D]
•
Alkaline phosphatases
•
Bone-specific alkaline phosphatase
•
Bicarbonate
•
FGF23
•
Bone histology, BMD
•
Vascular and valvular calcification imaging
•
Measures of GFR
•
Hospitalizations
•
Quality of life
•
Kidney or kidney graft failure
•
Fracture
•
Parathyroidectomy
•
Clinical adverse events
•
Growth, skeletal deformities, bone accrual
•
Calciphylaxis/CUA
4.2.4
In patients with CKD G5D, what is the evidence for benefit or harm in treating with
calcitriol, vitamin D analogs, calcimimetics or combination thereof compared with
placebo or active control in terms of biochemical outcomes, other surrogate outcomes,
and patient-centered outcomes?
•
Mortality
•
Cardiovascular and cerebrovascular events
•
Fracture
•
Vascular and valvular calcification imaging
•
Calcium
•
Phosphate
•
Parathyroid hormone
•
25-hydroxyvitamin D [25(OH)D]
•
1,25-dihydroxyvitamin D [1,25(OH)2D]
•
Alkaline phosphatases
•
Bone-specific alkaline phosphatase
•
Bicarbonate
•
FGF23
•
Bone histology, BMD
•
Vascular and valvular calcification imaging
•
Measures of GFR
•
Hospitalizations
•
Quality of life
•
Kidney or kidney graft failure
•
Fracture
•
Parathyroidectomy
•
Clinical adverse events
•
Growth, skeletal deformities, bone accrual
•
Calciphylaxis/CUA
BMD, bone mineral density; CKD, chronic kidney disease; CUA, calcific uremic arteriolopathy;
GFR, glomerular filtration rate; FGF23, fibroblast growth factor 23; LVH, left ventricular
hypertrophy; PTH, parathyroid hormone; rec. no., recommendation number; TMV, bone
turnover mineralization volume.
In keeping with the standard KDIGO policy of maintaining transparency during the guideline
development process and attesting to its rigor, we conducted an open public review
of the draft CKD-MBD guideline update, and all feedback received was reviewed and
considered by the Work Group before finalizing this guideline document for publication.
The comments and suggestions greatly assisted us in shaping a final document that
we felt would be as valuable as possible to the entire nephrology community.
We wish to thank the Work Group co-chairs, Drs. Markus Ketteler and Mary Leonard,
along with all of the Work Group members, who volunteered countless hours of their
time to develop this guideline. We also thank Dr. Karen Robinson and her Evidence
Review Team at Johns Hopkins University, the KDIGO staff, and many others for their
support that made this project possible.
David C. Wheeler, MD, FRCP
Wolfgang C. Winkelmayer, MD, MPH, ScD
KDIGO Co-chairs
Work Group membership
Work Group Co-chairs
Markus Ketteler, MD, FERAKlinikum CoburgCoburg, Germany
Mary B. Leonard, MD, MSCEStanford University School of MedicineStanford, CA, USA
Work Group
Geoffrey A. Block, MDDenver NephrologyDenver, CO, USAPieter Evenepoel, MD, PhD, FERAUniversity
Hospitals LeuvenLeuven, BelgiumMasafumi Fukagawa, MD, PhD, FASNTokai University School
of MedicineIsehara, JapanCharles A. Herzog, MD, FACC, FAHAHennepin County Medical
CenterMinneapolis, MN, USALinda McCann, RD, CSREagle, ID, USASharon M. Moe, MDIndiana
University School of MedicineRoudebush Veterans Affairs Medical CenterIndianapolis,
IN, USA
Rukshana Shroff, MD, FRCPCH, PhDGreat Ormond Street Hospital for ChildrenNHS Foundation
Trust,London, UKMarcello A. Tonelli, MD, SM, FRCPCUniversity of CalgaryCalgary, CanadaNigel
D. Toussaint MBBS, FRACP, PhDThe Royal Melbourne HospitalUniversity of MelbourneMelbourne,
AustraliaMarc G. Vervloet, MD, PhD, FERAVU University Medical Center AmsterdamAmsterdam,
The Netherlands
Evidence Review Team
Johns Hopkins University
Baltimore, MD, USA
Karen A. Robinson, PhD, Associate Professor of Medicine and Project DirectorCasey
M. Rebholz, PhD, MPH, MS, Co-investigatorLisa M. Wilson, ScM, Project ManagerErmias
Jirru, MD, MPH, Research AssistantMarisa Chi Liu, MD, MPH, Research AssistantJessica
Gayleard, BS, Research AssistantAllen Zhang, BS, Research Assistant
Abstract
The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline
Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney
disease–mineral and bone disorder (CKD-MBD) represents a selective update of the prior
guideline published in 2009. This update, along with the 2009 publication, is intended
to assist the practitioner caring for adults and children with CKD, those on chronic
dialysis therapy, or individuals with a kidney transplant. Specifically, the topic
areas for which updated recommendations are issued include diagnosis of bone abnormalities
in CKD-MBD; treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance,
treatment of abnormalities in parathyroid hormone in CKD-MBD; treatment of bone abnormalities
by antiresorptives and other osteoporosis therapies; and evaluation and treatment
of kidney transplant bone disease. Development of this guideline update followed an
explicit process of evidence review and appraisal. Treatment approaches and guideline
recommendations are based on systematic reviews of relevant trials, and appraisal
of the quality of the evidence and the strength of recommendations followed the GRADE
(Grading of Recommendations Assessment, Development, and Evaluation) approach. Limitations
of the evidence are discussed, with areas of future research also presented.
Keywords: bone abnormalities; bone mineral density; calcium; chronic kidney disease;
CKD-MBD; dialysis; guideline; hyperparathyroidism; hyperphosphatemia; KDIGO; kidney
transplantation; mineral and bone disorder; parathyroid hormone; phosphate; phosphorus;
systematic review
CITATION
In citing this document, the following format should be used: Kidney Disease: Improving
Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline
Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney
Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59.
Summary of KDIGO CKD-MBD recommendations∗
Updated recommendations are denoted in boxes
Chapter 3.1: Diagnosis of CKD-MBD: biochemical abnormalities
3.1.1: We recommend monitoring serum levels of calcium, phosphate, PTH, and alkaline
phosphatase activity beginning in CKD G3a (1C). In children, we suggest such monitoring
beginning in CKD G2 (2D).
3.1.2: In patients with CKD G3a–G5D, it is reasonable to base the frequency of monitoring
serum calcium, phosphate, and PTH on the presence and magnitude of abnormalities,
and the rate of progression of CKD (Not Graded).
Reasonable monitoring intervals would be:
•
In CKD G3a–G3b: for serum calcium and phosphate, every 6–12 months; and for PTH, based
on baseline level and CKD progression.
•
In CKD G4: for serum calcium and phosphate, every 3–6 months; and for PTH, every 6–12
months.
•
In CKD G5, including G5D: for serum calcium and phosphate, every 1–3 months; and for
PTH, every 3–6 months.
•
In CKD G4–G5D: for alkaline phosphatase activity, every 12 months, or more frequently
in the presence of elevated PTH (see Chapter 3.2).
In CKD patients receiving treatments for CKD-MBD, or in whom biochemical abnormalities
are identified, it is reasonable to increase the frequency of measurements to monitor
for trends and treatment efficacy and side effects (Not Graded).
3.1.3: In patients with CKD G3a–G5D, we suggest that 25(OH)D (calcidiol) levels might
be measured, and repeated testing determined by baseline values and therapeutic interventions
(2C). We suggest that vitamin D deficiency and insufficiency be corrected using treatment
strategies recommended for the general population (2C).
3.1.4: In patients with CKD G3a–G5D, we recommend that therapeutic decisions be based
on trends rather than on a single laboratory value, taking into account all available
CKD-MBD assessments (1C).
3.1.5: In patients with CKD G3a–G5D, we suggest that individual values of serum calcium
and phosphate, evaluated together, be used to guide clinical practice rather than
the mathematical construct of calcium-phosphate product (Ca × P) (2D).
3.1.6: In reports of laboratory tests for patients with CKD G3a–G5D, we recommend
that clinical laboratories inform clinicians of the actual assay method in use and
report any change in methods, sample source (plasma or serum), or handling specifications
to facilitate the appropriate interpretation of biochemistry data (1B).
Chapter 3.2: Diagnosis of CKD-MBD: bone
3.2.1: In patients with CKD G3a–G5D with evidence of CKD-MBD and/or risk factors for
osteoporosis, we suggest BMD testing to assess fracture risk if results will impact
treatment decisions (2B).
3.2.2: In patients with CKD G3a–G5D, it is reasonable to perform a bone biopsy if
knowledge of the type of renal osteodystrophy will impact treatment decisions (Not
Graded).
3.2.3: In patients with CKD G3a–G5D, we suggest that measurements of serum PTH or
bone-specific alkaline phosphatase can be used to evaluate bone disease because markedly
high or low values predict underlying bone turnover (2B).
3.2.4: In patients with CKD G3a–G5D, we suggest not to routinely measure bone-derived
turnover markers of collagen synthesis (such as procollagen type I C-terminal propeptide)
and breakdown (such as type I collagen cross-linked telopeptide, cross-laps, pyridinoline,
or deoxypyridinoline) (2C).
3.2.5: We recommend that infants with CKD G2–G5D have their length measured at least
quarterly, while children with CKD G2–G5D should be assessed for linear growth at
least annually (1B).
Chapter 3.3: Diagnosis of CKD-MBD: vascular calcification
3.3.1: In patients with CKD G3a–G5D, we suggest that a lateral abdominal radiograph
can be used to detect the presence or absence of vascular calcification, and an echocardiogram
can be used to detect the presence or absence of valvular calcification, as reasonable
alternatives to computed tomography-based imaging (2C).
3.3.2: We suggest that patients with CKD G3a–G5D with known vascular or valvular calcification
be considered at highest cardiovascular risk (2A). It is reasonable to use this information
to guide the management of CKD-MBD (Not Graded).
Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphate and maintaining
serum calcium
4.1.1: In patients with CKD G3a–G5D, treatments of CKD-MBD should be based on serial
assessments of phosphate, calcium, and PTH levels, considered together (Not Graded).
4.1.2: In patients with CKD G3a–G5D, we suggest lowering elevated phosphate levels
toward the normal range (2C).
4.1.3: In adult patients with CKD G3a–G5D, we suggest avoiding hypercalcemia (2C).
In children with CKD G3a–G5D, we suggest maintaining serum calcium in the age-appropriate
normal range (2C).
4.1.4: In patients with CKD G5D, we suggest using a dialysate calcium concentration
between 1.25 and 1.50 mmol/l (2.5 and 3.0 mEq/l) (2C).
4.1.5: In patients with CKD G3a-G5D, decisions about phosphate-lowering treatment
should be based on progressively or persistently elevated serum phosphate (Not Graded).
4.1.6: In adult patients with CKD G3a–G5D receiving phosphate-lowering treatment,
we suggest restricting the dose of calcium-based phosphate binders (2B). In children
with CKD G3a–G5D, it is reasonable to base the choice of phosphate-lowering treatment
on serum calcium levels (Not Graded).
4.1.7: In patients with CKD G3a-G5D, we recommend avoiding the long-term use of aluminum-containing
phosphate binders and, in patients with CKD G5D, avoiding dialysate aluminum contamination
to prevent aluminum intoxication (1C).
4.1.8: In patients with CKD G3a–G5D, we suggest limiting dietary phosphate intake
in the treatment of hyperphosphatemia alone or in combination with other treatments
(2D). It is reasonable to consider phosphate source (e.g., animal, vegetable, additives)
in making dietary recommendations (Not Graded).
4.1.9: In patients with CKD G5D, we suggest increasing dialytic phosphate removal
in the treatment of persistent hyperphosphatemia (2C).
Chapter 4.2: Treatment of abnormal PTH levels in CKD-MBD
4.2.1: In patients with CKD G3a–G5 not on dialysis, the optimal PTH level is not known.
However, we suggest that patients with levels of intact PTH progressively rising or
persistently above the upper normal limit for the assay be evaluated for modifiable
factors, including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin
D deficiency (2C).
4.2.2: In adult patients with CKD G3a–G5 not on dialysis, we suggest that calcitriol
and vitamin D analogs not be routinely used (2C). It is reasonable to reserve the
use of calcitriol and vitamin D analogs for patients with CKD G4–G5 with severe and
progressive hyperparathyroidism (Not Graded).
In children, calcitriol and vitamin D analogs may be considered to maintain serum
calcium levels in the age-appropriate normal range (Not Graded).
4.2.3: In patients with CKD G5D, we suggest maintaining iPTH levels in the range of
approximately 2 to 9 times the upper normal limit for the assay (2C).
We suggest that marked changes in PTH levels in either direction within this range
prompt an initiation or change in therapy to avoid progression to levels outside of
this range (2C).
4.2.4: In patients with CKD G5D requiring PTH-lowering therapy, we suggest calcimimetics,
calcitriol, or vitamin D analogs, or a combination of calcimimetics with calcitriol
or vitamin D analogs (2B).
4.2.5: In patients with CKD G3a–G5D with severe hyperparathyroidism (HPT) who fail
to respond to medical or pharmacological therapy, we suggest parathyroidectomy (2B).
Chapter 4.3: Treatment of bone with bisphosphonates, other osteoporosis medications,
and growth hormone
4.3.1: In patients with CKD G1–G2 with osteoporosis and/or high risk of fracture,
as identified by World Health Organization criteria, we recommend management as for
the general population (1A).
4.3.2: In patients with CKD G3a–G3b with PTH in the normal range and osteoporosis
and/or high risk of fracture, as identified by World Health Organization criteria,
we suggest treatment as for the general population (2B).
4.3.3: In patients with CKD G3a–G5D with biochemical abnormalities of CKD-MBD and
low BMD and/or fragility fractures, we suggest that treatment choices take into account
the magnitude and reversibility of the biochemical abnormalities and the progression
of CKD, with consideration of a bone biopsy (2D).
4.3.4: In children and adolescents with CKD G2–G5D and related height deficits, we
recommend treatment with recombinant human growth hormone when additional growth is
desired, after first addressing malnutrition and biochemical abnormalities of CKD-MBD
(1A).
Chapter 5: Evaluation and treatment of kidney transplant bone disease
5.1: In patients in the immediate post–kidney transplant period, we recommend measuring
serum calcium and phosphate at least weekly, until stable (1B).
5.2: In patients after the immediate post–kidney transplant period, it is reasonable
to base the frequency of monitoring serum calcium, phosphate, and PTH on the presence
and magnitude of abnormalities, and the rate of progression of CKD (Not Graded).
Reasonable monitoring intervals would be:
•
In CKD G1T–G3bT, for serum calcium and phosphate, every 6–12 months; and for PTH,
once, with subsequent intervals depending on baseline level and CKD progression.
•
In CKD G4T, for serum calcium and phosphate, every 3–6 months; and for PTH, every
6–12 months.
•
In CKD G5T, for serum calcium and phosphate, every 1–3 months; and for PTH, every
3–6 months.
•
In CKD G3aT–G5T, measurement of alkaline phosphatases annually, or more frequently
in the presence of elevated PTH (see Chapter 3.2).
In CKD patients receiving treatments for CKD-MBD, or in whom biochemical abnormalities
are identified, it is reasonable to increase the frequency of measurements to monitor
for efficacy and side effects (Not Graded).
It is reasonable to manage these abnormalities as for patients with CKD G3a–G5 (see
Chapters 4.1 and 4.2) (Not Graded).
5.3: In patients with CKD G1T–G5T, we suggest that 25(OH)D (calcidiol) levels might
be measured, and repeated testing determined by baseline values and interventions
(2C).
5.4: In patients with CKD G1T–G5T, we suggest that vitamin D deficiency and insufficiency
be corrected using treatment strategies recommended for the general population (2C).
5.5: In patients with CKD G1T–G5T with risk factors for osteoporosis, we suggest that
BMD testing be used to assess fracture risk if results will alter therapy (2C).
5.6: In patients in the first 12 months after kidney transplant with an estimated
glomerular filtration rate greater than approximately 30 ml/min/1.73 m
2
and low BMD, we suggest that treatment with vitamin D, calcitriol/alfacalcidol, and/or
antiresorptive agents be considered (2D).
•
We suggest that treatment choices be influenced by the presence of CKD-MBD, as indicated
by abnormal levels of calcium, phosphate, PTH, alkaline phosphatases, and 25(OH)D
(2C).
•
It is reasonable to consider a bone biopsy to guide treatment (Not Graded).
There are insufficient data to guide treatment after the first 12 months.
5.7: In patients with CKD G4T–G5T with known low BMD, we suggest management as for
patients with CKD G4–G5 not on dialysis, as detailed in Chapters 4.1 and 4.2 (2C).
The 2017 updated recommendations resulted in renumbering of several adjacent guideline
statements. Specifically, 2009 Recommendation 4.1.6 now becomes 2017 Recommendation
4.1.7; 2009 Recommendation 4.1.8 now becomes 2017 Recommendation 4.1.9; 2009 Recommendation
4.3.5 now becomes 2017 Recommendation 4.3.4; and 2009 Recommendation 5.8 now becomes
2017 Recommendation 5.7.
Summary and comparison of 2017 updated and 2009 KDIGO CKD-MBD recommendations
2017 revised KDIGO CKD-MBD recommendations
2009 KDIGO CKD-MBD recommendations
Brief rationale for updating
3.2.1. In patients with CKD G3a–G5D with evidence of CKD-MBD and/or risk factors for
osteoporosis, we suggest BMD testing to assess fracture risk if results will impact
treatment decisions (2B).
3.2.2. In patients with CKD G3a–G5D with evidence of CKD-MBD, we suggest that BMD
testing not be performed routinely, because BMD does not predict fracture risk as
it does in the general population, and BMD does not predict the type of renal osteodystrophy
(2B).
Multiple new prospective studies have documented that lower DXA BMD predicts incident
fractures in patients with CKD G3a–G5D. The order of these first 2 recommendations
was changed because a DXA BMD result might impact the decision to perform a bone biopsy.
3.2.2. In patients with CKD G3a–G5D, it is reasonable to perform a bone biopsy if
knowledge of the type of renal osteodystrophy will impact treatment decisions (Not
Graded).
3.2.1. In patients with CKD G3a–G5D, it is reasonable to perform a bone biopsy in
various settings including, but not limited to: unexplained fractures, persistent
bone pain, unexplained hypercalcemia, unexplained hypophosphatemia, possible aluminum
toxicity, and prior to therapy with bisphosphonates in patients with CKD-MBD (Not
Graded).
The primary motivation for this revision was the growing experience with osteoporosis
medications in patients with CKD, low BMD, and a high risk of fracture. The inability
to perform a bone biopsy may not justify withholding antiresorptive therapy from patients
at high risk of fracture.
4.1.1. In patients with CKD G3a–G5D, treatments of CKD-MBD should be based on serial
assessments of phosphate, calcium, and PTH levels, considered together (Not Graded).
This new recommendation was provided in order to emphasize the complexity and interaction
of CKD-MBD laboratory parameters.
4.1.2. In patients with CKD G3a–G5D, we suggest lowering elevated phosphate levels
toward the normal range (2C).
4.1.1. In patients with CKD G3a–G5, we suggest maintaining serum phosphate in the
normal range (2C). In patients with CKD G5D, we suggest lowering elevated phosphate
levels toward the normal range (2C).
There is an absence of data supporting that efforts to maintain phosphate in the normal
range are of benefit to CKD G3a–G4 patients, including some safety concerns. Treatment
should aim at overt hyperphosphatemia.
4.1.3. In adult patients with CKD G3a–G5D, we suggest avoiding hypercalcemia (2C).In
children with CKD G3a–G5D, we suggest maintaining serum calcium in the age-appropriate
normal range (2C).
4.1.2. In patients with CKD G3a–G5D, we suggest maintaining serum calcium in the normal
range (2D).
Mild and asymptomatic hypocalcemia (e.g., in the context of calcimimetic treatment)
can be tolerated in order to avoid inappropriate calcium loading in adults.
4.1.4. In patients with CKD G5D, we suggest using a dialysate calcium concentration
between 1.25 and 1.50 mmol/l (2.5 and 3.0 mEq/l) (2C).
4.1.3. In patients with CKD G5D, we suggest using a dialysate calcium concentration
between 1.25 and 1.50 mmol/l (2.5 and 3.0 mEq/l) (2D).
Additional studies of better quality are available; however, these do not allow for
discrimination of benefits and harms between calcium dialysate concentrations of 1.25
and 1.50 mmol/l (2.5 and 3.0 mEq/l). Hence, the wording is unchanged, but the evidence
grade is upgraded from 2D to 2C.
4.1.5. In patients with CKD G3a–G5D, decisions about phosphate-lowering treatment
should be based on progressively or persistently elevated serum phosphate (Not Graded).
4.1.4. In patients with CKD G3a–G5 (2D) and G5D (2B), we suggest using phosphate-binding
agents in the treatment of hyperphosphatemia. It is reasonable that the choice of
phosphate binder takes into account CKD stage, presence of other components of CKD-MBD,
concomitant therapies, and side effect profile (Not Graded).
Emphasizes the perception that early “preventive” phosphate-lowering treatment is
currently not supported by data (see Recommendation 4.1.2).The broader term “phosphate-lowering”
treatment is used instead of phosphate binding agents since all possible approaches
(i.e., binders, diet, dialysis) can be effective.
4.1.6. In adult patients with CKD G3a–G5D receiving phosphate-lowering treatment,
we suggest restricting the dose of calcium-based phosphate binder (2B). In children
with CKD G3a–G5D, it is reasonable to base the choice of phosphate-lowering treatment
on serum calcium levels (Not Graded).
4.1.5. In patients with CKD G3a–G5D and hyperphosphatemia, we recommend restricting
the dose of calcium-based phosphate binders and/or the dose of calcitriol or vitamin
D analog in the presence of persistent or recurrent hypercalcemia (1B).
New evidence from 3 RCTs supports a more general recommendation to restrict calcium-based
phosphate binders in hyperphosphatemic patients across all severities of CKD.
In patients with CKD G3a–G5D and hyperphosphatemia, we suggest restricting the dose
of calcium-based phosphate binders in the presence of arterial calcification (2C)
and/or adynamic bone disease (2C) and/or if serum PTH levels are persistently low
(2C).
4.1.8. In patients with CKD G3a–G5D, we suggest limiting dietary phosphate intake
in the treatment of hyperphosphatemia alone or in combination with other treatments
(2D). It is reasonable to consider phosphate source (e.g., animal, vegetable, additives)
in making dietary recommendations (Not Graded).
4.1.7. In patients with CKD G3a–G5D, we suggest limiting dietary phosphate intake
in the treatment of hyperphosphatemia alone or in combination with other treatments
(2D).
New data on phosphate sources were deemed to be included as an additional qualifier
to the previous recommendation.
4.2.1. In patients with CKD G3a–G5 not on dialysis, the optimal PTH level is not known.
However, we suggest that patients with levels of intact PTH progressively rising or
persistently above the upper normal limit for the assay be evaluated for modifiable
factors, including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin
D deficiency (2C).
4.2.1. In patients with CKD G3a–G5 not on dialysis, the optimal PTH level is not known.
However, we suggest that patients with levels of intact PTH above the upper normal
limit of the assay are first evaluated for hyperphosphatemia, hypocalcemia, and vitamin
D deficiency (2C).It is reasonable to correct these abnormalities with any or all
of the following: reducing dietary phosphate intake and administering phosphate binders,
calcium supplements, and/or native vitamin D (Not Graded).
The Work Group felt that modest increases in PTH may represent an appropriate adaptive
response to declining kidney function and has revised this statement to include “persistently”
above the upper normal PTH level as well as “progressively rising” PTH levels, rather
than “above the upper normal limit.” That is, treatment should not be based on a single
elevated value.
4.2.2. In adult patients with CKD G3a–G5 not on dialysis, we suggest that calcitriol
and vitamin D analogs not be routinely used. (2C) It is reasonable to reserve the
use of calcitriol and vitamin D analogs for patients with CKD G4–G5 with severe and
progressive hyperparathyroidism (Not Graded).
4.2.2. In patients with CKD G3a–G5 not on dialysis, in whom serum PTH is progressively
rising and remains persistently above the upper limit of normal for the assay despite
correction of modifiable factors, we suggest treatment with calcitriol or vitamin
D analogs (2C).
Recent RCTs of vitamin D analogs failed to demonstrate improvements in clinically
relevant outcomes but demonstrated increased risk of hypercalcemia.
In children, calcitriol and vitamin D analogs may be considered to maintain serum
calcium levels in the age-appropriate normal range (Not Graded).
4.2.4. In patients with CKD G5D requiring PTH-lowering therapy, we suggest calcimimetics,
calcitriol, or vitamin D analogs, or a combination of calcimimetics with calcitriol
or vitamin D analogs (2B).
4.2.4. In patients with CKD G5D and elevated or rising PTH, we suggest calcitriol,
or vitamin D analogs, or calcimimetics, or a combination of calcimimetics and calcitriol
or vitamin D analogs be used to lower PTH (2B).
•
It is reasonable that the initial drug selection for the treatment of elevated PTH
be based on serum calcium and phosphate levels and other aspects of CKD-MBD (Not Graded).
•
It is reasonable that calcium or non-calcium-based phosphate binder dosage be adjusted
so that treatments to control PTH do not compromise levels of phosphate and calcium
(Not Graded).
•
We recommend that, in patients with hypercalcemia, calcitriol or another vitamin D
sterol be reduced or stopped (1B).
•
We suggest that, in patients with hyperphosphatemia, calcitriol or another vitamin
D sterol be reduced or stopped (2D).
•
We suggest that, in patients with hypocalcemia, calcimimetics be reduced or stopped
depending on severity, concomitant medications, and clinical signs and symptoms (2D).
•
We suggest that, if the intact PTH levels fall below 2 times the upper limit of normal
for the assay, calcitriol, vitamin D analogs, and/or calcimimetics be reduced or stopped
(2C).
This recommendation originally had not been suggested for updating by the KDIGO Controversies
Conference in 2013. However, due to a subsequent series of secondary and post hoc
publications of the EVOLVE trial, the Work Group decided to reevaluate Recommendation
4.2.4 as well. Although EVOLVE did not meet its primary endpoint, the majority of
the Work Group members were reluctant to exclude potential benefits of calcimimetics
for G5D patients based on subsequent prespecified analyses. The Work Group, however,
decided not to prioritize any PTH-lowering treatment at this time because calcimimetics,
calcitriol, or vitamin D analogs are all acceptable first-line options in G5D patients.
4.3.3. In patients with CKD G3a–G5D with biochemical abnormalities of CKD-MBD and
low BMD and/or fragility fractures, we suggest that treatment choices take into account
the magnitude and reversibility of the biochemical abnormalities and the progression
of CKD, with consideration of a bone biopsy (2D).
4.3.3. In patients with CKD G3a–G3b with biochemical abnormalities of CKD-MBD and
low BMD and/or fragility fractures, we suggest that treatment choices take into account
the magnitude and reversibility of the biochemical abnormalities and the progression
of CKD, with consideration of a bone biopsy (2D).
Recommendation 3.2.2 now addresses the indications for a bone biopsy prior to antiresorptive
and other osteoporosis therapies. Therefore, 2009 Recommendation 4.3.4 has been removed
and 2017 Recommendation 4.3.3 is broadened from CKD G3a–G3b to CKD G3a–G5D.
4.3.4. In patients with CKD G4–G5D having biochemical abnormalities of CKD-MBD, and
low BMD and/or fragility fractures, we suggest additional investigation with bone
biopsy prior to therapy with antiresorptive agents (2C).
5.5. In patients with G1T–G5T with risk factors for osteoporosis, we suggest that
BMD testing be used to assess fracture risk if results will alter therapy (2C).
5.5. In patients with an estimated glomerular filtration rate greater than approximately
30 ml/min/1.73 m2, we suggest measuring BMD in the first 3 months after kidney transplant
if they receive corticosteroids, or have risk factors for osteoporosis as in the general
population (2D).
2009 Recommendations 5.5 and 5.7 were combined to yield 2017 Recommendation 5.5.
5.7. In patients with CKD G4T–G5T, we suggest that BMD testing not be performed routinely,
because BMD does not predict fracture risk as it does in the general population and
BMD does not predict the type of kidney transplant bone disease (2B).
5.6. In patients in the first 12 months after kidney transplant with an estimated
glomerular filtration rate greater than approximately 30 ml/min/1.73 m2 and low BMD,
we suggest that treatment with vitamin D, calcitriol/alfacalcidol, and/or antiresorptive
agents be considered (2D).
•
We suggest that treatment choices be influenced by the presence of CKD-MBD, as indicated
by abnormal levels of calcium, phosphate, PTH, alkaline phosphatases, and 25(OH)D
(2C).
•
It is reasonable to consider a bone biopsy to guide treatment (Not Graded).
There are insufficient data to guide treatment after the first 12 months.
5.6. In patients in the first 12 months after kidney transplant with an estimated
glomerular filtration rate greater than approximately 30 ml/min/1.73 m2 and low BMD,
we suggest that treatment with vitamin D, calcitriol/alfacalcidol, or bisphosphonates
be considered (2D).
•
We suggest that treatment choices be influenced by the presence of CKD-MBD, as indicated
by abnormal levels of calcium, phosphate, PTH, alkaline phosphatases, and 25(OH)D
(2C).
•
It is reasonable to consider a bone biopsy to guide treatment, specifically before
the use of bisphosphonates due to the high incidence of adynamic bone disease (Not
Graded).
There are insufficient data to guide treatment after the first 12 months.
The second bullet is revised, consistent with the new bone biopsy recommendation (i.e.,
2017 Recommendation 3.2.2).
25(OH)D, 25-hydroxyvitamin D; BMD, bone mineral density; CKD, chronic kidney disease;
CKD-MBD, chronic kidney disease–mineral bone disorder; DXA, dual-energy x-ray absorptiometry;
PTH, parathyroid hormone; RCT, randomized controlled trial. Changes to above summarized
recommendations resulted in renumbering of several adjacent guideline statements.
Specifically, 2009 Recommendation 4.1.6 now becomes 2017 Recommendation 4.1.7; 2009
Recommendation 4.1.8 now becomes 2017 Recommendation 4.1.9; 2009 Recommendation 4.3.5
now becomes 2017 Recommendation 4.3.4; and 2009 Recommendation 5.8 now becomes 2017
Recommendation 5.7.
Chapter 3.2: Diagnosis of CKD-MBD: bone
3.2.1: In patients with CKD G3a–G5D with evidence of CKD-MBD and/or risk factors for
osteoporosis, we suggest BMD testing to assess fracture risk if results will impact
treatment decisions (2B).
Rationale
It is well established that patients with CKD G3a–G5D have increased fracture rates
compared with the general population,2, 3, 4 and moreover, incident hip fractures
are associated with substantial morbidity and mortality.5, 6, 7, 8, 9 At the time
of the 2009 KDIGO CKD-MBD guideline, publications addressing the ability of dual-energy
X-ray absorptiometry (DXA) measures of bone mineral density (BMD) to estimate fracture
risk in CKD were limited to cross-sectional studies comparing BMD in CKD patients
with and without a prevalent fracture. The results were variable across studies and
across skeletal sites. In light of the lack of evidence that DXA BMD predicted fractures
in CKD patients as it does in the general population, and the inability of DXA to
indicate the histological type of bone disease, the 2009 Guideline recommended that
BMD testing not be performed routinely in patients with CKD G3a to G5D with CKD-MBD.
Furthermore, the lack of clinical trials in patients with low BMD and CKD also limited
the enthusiasm for measuring BMD in the first place.
The current evidence-based review identified 4 prospective cohort studies of DXA BMD
and incident fractures in adults with CKD G3a to G5D (Supplementary Tables S7–S12).
These studies demonstrated that DXA BMD predicted fractures across the spectrum from
CKD G3a to G5D (Supplementary Tables S7–S12).10, 11, 12, 13 In the earliest study,
DXA BMD was measured annually in 485 hemodialysis (HD) patients (mean age: 60 years)
in a single center in Japan.
10
In adjusted Cox proportional analyses, lower baseline femoral neck and total hip BMD
predicted a greater risk of fracture; for example, the hazard ratio (HR) was 0.65
(95% confidence interval [CI]: 0.47–0.90) for each standard deviation (SD) higher
femoral neck BMD. In receiver operating characteristic (ROC) analyses stratified according
to parathyroid hormone (PTH) below or above the median value of 204 pg/ml (21.6 pmol/l),
the area under the curve (AUC) for femoral neck BMD was 0.717 in the lower stratum
and 0.512 in the higher stratum. Of note, higher serum bone-specific alkaline phosphate
levels also predicted incident fractures.
In the second study, Yenchek et al. assessed whether DXA total hip and femoral neck
BMD were associated with incident nonspine fragility fractures in participants with
estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 and without CKD in
the Health, Aging and Body Composition Study, a prospective study of community-living
individuals, 70 to 79 years of age at enrollment.
13
A total of 587 (21%) of the 2754 participants had CKD, and among those, 83% and 13%
had CKD G3a and G3b, respectively. In adjusted analyses, the fracture HR for each
SD lower femoral neck BMD was 2.14 (95% CI: 1.80–2.55) in participants without CKD,
and 2.69 (95% CI: 1.96–3.69) in those with CKD. Similar results were observed for
total hip BMD. When limited to hip fractures, the adjusted femoral neck BMD HRs were
5.82 (95% CI: 3.27–10.35) among those with CKD and 3.08 (95% CI: 2.29–4.14) among
those without CKD. Interaction terms demonstrated that the association of BMD with
fracture did not differ in those with versus without CKD. However, the association
of femoral neck BMD with fracture was significantly less pronounced (test for interaction,
P = 0.04) among those with PTH > 65 pg/ml (6.9 pmol/l; HR: 1.56, 95% CI: 0.90–2.70)
compared with those with a PTH ≤ 65 pg/ml (6.9 pmol/l; HR: 2.41, 95% CI: 2.04–2.85)
in all participants combined. This is noteworthy in light of the similar pattern observed
in dialysis patients, as described above.
10
West et al. reported the results of a prospective cohort study of 131 predialysis
participants, mean age 62 years, followed up over a 2-year interval.
12
At baseline, the proportions with CKD G3a to G3b, G4, and G5 were 34%, 40%, and 26%,
respectively. DXA BMD was measured in the total hip, lumbar spine, and ultradistal
and one-third radius at baseline and 2 years. Low BMD at all sites, and a greater
annualized percentage decrease in BMD predicted fracture. For example, in multivariate
models, each SD lower total hip BMD was associated with an odds ratio (OR) of fracture
of 1.75 (95% CI: 1.30–2.20). The ROC AUC ranged from 0.62 in the spine to 0.74 in
the ultradistal radius in adjusted models.
Most recently, Naylor, et al.
11
assessed the ability of the Fracture Risk Assessment Tool (FRAX) to predict a major
osteoporotic fracture in 2107 adults ≥ 40 years of age in the Canadian Multicenter
Osteoporosis Study, including 320 with an eGFR ≤ 60 ml/min/1.73 m2. Of these, 72%
and 24% had CKD G3a and G3b, respectively. FRAX with BMD, FRAX without BMD, and the
femoral neck T-score all predicted fractures (AUC: 0.65 to 0.71); the AUC was highest
for femoral neck T-score with inclusion of fall history. Importantly, the AUCs did
not differ between those with and without CKD.
There is growing evidence that DXA BMD predicts fractures in healthy children and
adolescents, and those with chronic disease.14, 15 However, no studies have examined
the associations among DXA BMD and fractures in children and adolescents with CKD.
In light of the lack of evidence that the ability of DXA BMD to predict fracture in
children with CKD is different than in adults, no specific recommendations are provided
for children. However, it should be noted that children and adolescents with CKD frequently
exhibit substantial growth failure. Given that DXA measures of areal BMD (g/cm2) underestimate
volumetric BMD (g/cm3) in children with short stature,
16
DXA results should be adjusted for bone size, consistent with the 2013 International
Society of Clinical Densitometry (ISCD) Pediatric Official Positions.
17
Prediction equations to adjust DXA results for height Z-score are now available,
16
and the impact on DXA BMD Z-scores in children with CKD is substantial.
18
Finally, a single-center study in 171 children with CKD G2 to G5D reported that lower
cortical volumetric BMD in the tibia, as measured by peripheral quantitative computed
tomography (CT), predicted fractures over a 1-year interval (Supplementary Tables S7–S12).
19
The HR per unit lower cortical BMD Z-score was 1.75 (95% CI: 1.15–2.67; P < 0.01).
The evidence-based review also evaluated clinical trials of the effects of osteoporosis
medications on BMD in CKD G3a to G5D (Supplementary Tables S1–S6). Prior analyses
of large randomized clinical trials (RCTs) evaluating medications for the treatment
of postmenopausal osteoporosis (risedronate, alendronate, teriparatide, and raloxifene)
were described in the 2009 Guideline. These trials specifically excluded patients
with an elevated serum creatinine, hyperparathyroidism, or abnormal alkaline phosphate
levels (i.e., CKD-MBD).20, 21, 22, 23 However, post hoc analyses found that these
drugs had similar efficacy on improving BMD and reducing fracture incidence in individuals
with moderately reduced eGFR, compared with those with mildly decreased or normal
eGFR. Three new trials were identified. The denosumab study was also a post hoc analysis
of an RCT in women with postmenopausal osteoporosis and normal PTH levels.
24
The analysis demonstrated efficacy of denosumab in decreasing fracture risk and increasing
BMD in 2817 women with CKD G3a to G3b and 73 with CKD G4. Here, the risk of hypocalcemia
associated with denosumab in advanced CKD requires mentioning. The remaining 2 new
trials on alendronate
25
and raloxifene
26
were small studies (<60 participants) that did not exclude patients with evidence
of CKD-MBD. These studies did not show consistent beneficial effects on DXA BMD. Generally,
a major limitation is the lack of data on fracture prevention by such therapeutic
interventions in advanced CKD (especially in CKD G5–G5D).
In summary, the aforementioned 4 prospective studies evaluating BMD testing in adults
with CKD represent a substantial advance since the original guideline from 2009. Despite
the fact that they were conducted across a spectrum of CKD severity, the finding that
hip BMD predicted fractures was consistent across studies, and 2 studies demonstrated
associations comparable to those seen in the absence of CKD.11, 13 Based on these
insights, if a low or declining BMD will lead to additional interventions to reduce
falls or use osteoporosis medications, then BMD assessment is reasonable.
Research recommendations
•
RCTs are needed to determine whether interventions based on DXA BMD are associated
with lower fracture rates, and whether the effects vary based on clinical variables
such as the baseline PTH level, underlying cause of kidney disease, and CKD GFR category.
•
Prospective studies are needed to determine whether alternative imaging techniques,
such as quantitative CT, improve fracture prediction in CKD.
•
Prospective studies are needed in children and adolescents to determine whether DXA
predicts fractures in children and to determine whether the ISCD recommendations to
measure whole-body and spine BMD in children are the appropriate sites in the context
of CKD.
17
Hip and radius BMD pediatric reference data are now available and predict incident
fractures in healthy children and adolescents.27, 28
3.2.2: In patients with CKD G3a–G5D, it is reasonable to perform a bone biopsy if
knowledge of the type of renal osteodystrophy will impact treatment decisions (Not
Graded).
Rationale
Renal osteodystrophy is defined as abnormal bone histology and is 1 component of the
bone abnormalities of CKD-MBD.
29
Bone biopsy is the gold standard for the diagnosis and classification for renal osteodystrophy.
As detailed in the 2009 KDIGO CKD-MBD Guideline,
30
DXA BMD does not distinguish among types of renal osteodystrophy, and the diagnostic
utility of biochemical markers is limited by poor sensitivity and specificity. Differences
in PTH assays (e.g., intact vs. whole PTH) and reference ranges have contributed to
differences across studies. Unfortunately, cross-sectional studies have provided conflicting
information on the use of biomarkers to predict underlying bone histology. This is
not surprising given the short half-lives of most of the circulating biomarkers, and
the long (3–6 months) bone remodeling (turnover) cycle.
KDIGO recently led an international consortium to conduct a cross-sectional retrospective
diagnostic study of biomarkers (all run in a single laboratory) and bone biopsies
in 492 dialysis patients.
31
The objective was to determine the predictive value of PTH (determined by both intact
PTH [iPTH] and whole PTH assays), bone-specific alkaline phosphatase (bALP), and amino-terminal
propeptide of type 1 procollagen (P1NP) as markers of bone turnover. Although iPTH,
whole PTH, and bALP levels were associated with bone turnover, no biomarker singly
or in combination was sufficiently robust to diagnose low, normal, and high bone turnover
in an individual patient. The conclusion was in support of the 2009 KDIGO Guideline
to use trends in PTH rather than absolute “target” values when making decisions as
to whether to start or stop treatments to lower PTH. Table 1 provides the sensitivity,
specificity, and positive and negative predictive value of PTH in helping clinicians
determine therapies, demonstrating the challenges clinicians face. Thus, the Work
Group encourages the continued use of trends in PTH to guide therapy, and when trends
in PTH are inconsistent, a bone biopsy should be considered.
Table 1
Utility of KDOQI and KDIGO PTH thresholds for diagnostic decision making
KDOQI∗
KDIGO+
Sens
Spec
PPV
NPV
Sens
Spec
PPV
NPV
Differentiating low-turnover from non–low-turnover bone disease, or “When do I stop
therapy?”
69%
61%
72%
58%
66%
65%
73%
57%
Differentiating high-turnover from non–high-turnover bone disease, or “When do I start
therapy?”
58%
78%
35%
90%
37%
86%
35%
87%
iPTH, intact parathyroid hormone; KDIGO, Kidney Disease: Improving Global Outcomes;
KDOQI, Kidney Disease Outcomes Quality Initiative; NPV, negative predictive value;
PPV, positive predictive value; PTH, parathyroid hormone; Sens, sensitivity; Spec,
specificity.
∗
Using serum iPTH < 150 pg/ml (16 pmol/l) for lower and > 300 pg/ml (32 pmol/l) for
upper threshold.
+
Using serum iPTH < 130 pg/ml (14 pmol/l) for lower and > 585 pg/ml (62 pmol/l) for
upper threshold (2X and 9X of upper limit of normal for assay).
Reproduced with permission from Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic
accuracy of bone turnover markers and bone histology in patients with CKD treated
by dialysis. Am J Kidney Dis. 2016;67:559–566.
A bone biopsy should also be considered in patients with unexplained fractures, refractory
hypercalcemia, suspicion of osteomalacia, an atypical response to standard therapies
for elevated PTH, or progressive decreases in BMD despite standard therapy. The goal
of a bone biopsy would be to: (i) rule out atypical or unexpected bone pathology;
(ii) determine whether the patient has high- or low-turnover disease, which may alter
the dose of medications to treat renal osteodystrophy (e.g., initiate or discontinue
calcimimetics, calcitriol, or vitamin D analogs); or (iii) identify a mineralization
defect that would alter treatment (e.g., stop intake of aluminum, or aggressively
treat hypophosphatemia or vitamin D deficiency).
The 2009 Guideline recommended a bone biopsy prior to antiresorptive therapy in patients
with CKD G4 to G5D and evidence of biochemical abnormalities of CKD-MBD, low BMD,
and/or fragility fractures. The rationale was that low BMD may be due to CKD-MBD (e.g.,
high PTH) and that lowering PTH is a safer and more appropriate therapy than an antiresorptive.
In addition, there was concern that bisphosphonates would induce low-turnover bone
disease. This was based on a single cross-sectional study in 13 patients with CKD
G2 to G4 that were referred for bone biopsy after a variable duration of bisphosphonate
therapy.
32
To date, studies in patients with CKD have not definitively demonstrated that bisphosphonates
cause adynamic bone disease. Furthermore, the concerns in patients with CKD are only
theoretical, as it is well established that antiresorptive medications suppress bone
formation rates, even in the absence of kidney disease. For example, in an RCT of
zoledronic acid for the treatment of postmenopausal osteoporosis, bALP levels were
59% lower in the zoledronic acid group compared with the placebo group at 12 months.
33
Despite these limitations, in weighing the risk-benefit ratio of bisphosphonate treatment,
the 2009 KDIGO Guideline suggested a biopsy prior to therapy. Since 2009, an additional
antiresorptive treatment (denosumab) has proven to be effective in CKD G3a to G3b
and G4, as discussed in Recommendation 3.2.1. The growing experience with osteoporosis
medications in patients with CKD increases the comfort of treating patients with low
BMD and a high risk of fracture with antiresorptive therapy, although definitive trials
are lacking. Furthermore, additional data clearly support that the incidence of fracture
is markedly increased in patients with CKD, and thus the inability to perform a bone
biopsy may not justify withholding antiresorptive therapy to patients at high risk
of fracture. Thus, the Work Group voted to remove the requirement of bone biopsy prior
to the use of antiresorptive therapy for osteoporosis because the use of these drugs
must be individualized in patients with CKD. However, it is still prudent that these
drugs be used with caution and that the underlying renal osteodystrophy be addressed
first. With regard to efficacy, one may speculate that antiresorptive therapies confer
less benefit in the absence of activated osteoclasts, as is the case in adynamic bone
disease. Moreover, additional side effects such as acute kidney injury may also merit
consideration in CKD G3a to G5.
In summary, bone biopsy is the gold standard for the assessment of renal osteodystrophy
and should be considered in patients in whom the etiology of clinical symptoms and
biochemical abnormalities is in question, and the results may lead to changes in therapy.
With this statement, the Work Group is well aware that experience concerning performance
and evaluation of bone biopsies is limited in many centers.
34
With this in mind, in addition to the growing evidence that antiresorptive therapies
are effective in patients with CKD G3a to G3b and G4, and the lack of robust evidence
that these medications induce adynamic bone disease, the guideline no longer suggests
that a bone biopsy be performed prior to initiation of these medications.
Research recommendation
•
Prospective studies of circulating biomarkers are needed to determine whether they
can predict changes in bone histology.
Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphate and maintaining
serum calcium
4.1.1: In patients with CKD G3a–G5D, treatments of CKD-MBD should be based on serial
assessments of phosphate, calcium, and PTH levels, considered together (Not Graded).
Rationale
The previous Recommendation 4.1.1 from the 2009 KDIGO CKD-MBD guideline gave treatment
directions concerning serum phosphate levels in different GFR categories of CKD. The
accumulated evidence on this issue to date is now depicted in Supplementary Tables S49–S51,
S53–S55. Results of this evidence review can be summarized as follows: most studies
showed increasing risk of all-cause mortality with increasing levels of serum phosphate
in a consistent and direct fashion, with moderate risk of bias and low quality of
evidence, thus not essentially different from the study results before 2009. For GFR
decline and cardiovascular event rate, results were considered less conclusive.
Serum phosphate, calcium, and PTH concentrations are all routinely measured in CKD
patients, and clinical decisions are often made based on these values. However, the
results of these tests are influenced by food intake, adherence to and the timing
of drug intake and dietary modifications, differences in assay methods and their intra-assay
coefficient of variation (CV), and also by the interval from the last dialysis session
in CKD G5D patients. Furthermore, it has recently been suggested that these markers
undergo significant diurnal changes even in CKD patients.35, 36 Accordingly, the decision
should be based not on a single result, but rather on the trends of serial results,
which stands very much in accordance to 2009 Recommendation 3.1.4. In addition, recent
post hoc analyses of large dialysis cohorts suggest that the prognostic implications
of individual biochemical components of CKD-MBD largely depend on their context with
regard to constellations of the full array of MBD biomarkers.
37
This analysis identified a wide range of CKD-MBD phenotypes, based on phosphate, calcium,
and PTH measurements categorized into mutually exclusive categories of low, medium,
and high levels using previous Kidney Disease Outcomes Quality Initiative (KDOQI)/KDIGO
guideline targets, further illustrating important potential interactions between components
of CKD-MBD in terms of risk prediction for death or cardiovascular events. This analysis,
however, did not provide guidance for treatment, because it is unknown whether switching
from “risk classes” parallels changes in incidence of complications or mortality over
time. Of note, biomarkers such as bALP and 25(OH)vitamin D were also still considered
valuable, but as no new evidence has been published on their account, recommendations
remained unchanged from the previous guideline (2009 Recommendations 3.1.3, 3.2.3).
Finally, therapeutic maneuvers aimed at improving 1 parameter often have unintentional
effects on other parameters, as exemplified by the recent EVOLVE trial.
38
The guideline Work Group considered it reasonable to take the context of therapeutic
interventions into account when assessing values of phosphate, calcium, and PTH, and
felt that it was important to emphasize the interdependency of these biochemical parameters
for clinical therapeutic decision making.
Based on these assumptions, it was also decided to split previous 2009 Recommendation
4.1.1 into 2 new Recommendations, 4.1.1 (diagnostic recommendation based on accumulated
observational evidence) and 4.1.2 (therapeutic recommendation based mostly on RCTs).
Research recommendations
•
Prospective cohort studies or RCTs are needed to evaluate whether changes in CKD-MBD
risk marker patterns over time associate with changes in risk (e.g., multiple interventions).
•
Prospective cohort studies or RCTs are needed to examine whether biochemical abnormalities
of CKD-MBD must be weighed differently when induced by pharmacotherapy compared with
baseline values (e.g., past experience with hemoglobin as risk predictor vs. active
treatment to targets by erythropoiesis-stimulating agents).
•
Investigations contributing to the understanding of the usefulness of fibroblast growth
factor 23 (FGF23) as a complementary marker for treatment indications (e.g., phosphate-lowering
therapies to halt CKD progression) and direct treatment target (e.g., regression of
left ventricular hypertrophy [LVH]) should be undertaken.
4.1.2: In patients with CKD G3a–G5D, we suggest lowering elevated phosphate levels
toward the normal range (2C).
Rationale
As outlined above, since publication of the 2009 KDIGO CKD-MBD Guideline, additional
high-quality evidence now links higher concentrations of phosphate with mortality
among patients with CKD G3a to G5 or after transplantation39, 40, 41, 42, 43, 44,
45, 46, 47, 48 (Supplementary Tables S49–S51, S53–S55), although some studies did
not confirm this association.49, 50 However, trial data demonstrating that treatments
that lower serum phosphate will improve patient-centered outcomes are still lacking,
and therefore the strength of this recommendation remains weak (2C). The rationale
of interventions, therefore, is still only based on epidemiological evidence as described
above and biological plausibility pointing to possible phosphorus toxicity as recently
summarized.
51
Three recent historical cohort analyses from DOPPS, ArMORR, and COSMOS were not eligible
for this evidence-based review; however, it is noteworthy that these analyses suggested
that those dialysis patients who had been prescribed phosphate-binder therapy showed
improved survival.52, 53, 54 It is important to note that phosphate-binder prescription
was associated with better nutritional status. Indeed, correction for markers of nutritional
status in the DOPPS study did mitigate the strength of the association, yet a statistically
significant benefit persisted. In addition, propensity scoring attempting to correct
for selection bias and subgroup analysis applied by Isakova et al.
53
in the ArMORR cohort suggested robustness of the beneficial findings for those treated
with phosphate binders. However, residual confounding still cannot be completely ruled
out, and due to the nature of the observational data, these studies did not affect
the current recommendation.
Methods to prevent the development of hyperphosphatemia essentially include dietary
modification, the use of phosphate-lowering therapy, and intensified dialysis schedules
for those with CKD G5D. In the 2009 KDIGO Guideline it was suggested to maintain serum
phosphate in the normal range in the predialysis setting and lower serum phosphate
toward the normal range in patients on dialysis. Interestingly, in the prospective
observational COSMOS study cohort of HD patients (Supplementary Tables S49–S51, S53–S55),
the best patient survival was observed with serum phosphate close to 4.4 mg/dl (1.42
mmol/l).
55
The previous recommendation suggested that clinicians “maintain serum phosphate in
the normal range” for patients with CKD G3a to G3b and G4. The Work Group reevaluated
the evidence underlying this assumption. The majority of studies (Supplementary Table S49)
found phosphate to be consistently associated with excess mortality at levels above
and below the limits of normal, but not in the normal range.40, 41, 42, 43, 47, 48,
56, 57 This finding is in line with the previously found U-shaped relation of phosphate
with mortality risk in dialysis patients.
58
However, a recent trial comparing placebo with active phosphate-binder therapy in
predialysis patients (CKD G3b–G4) with a mean baseline phosphate concentration of
4.2 mg/dl (1.36 mmol/l), found a minimal decline in serum phosphate, no effect on
FGF23, and increases in coronary calcification scores for the active treatment group
59
—calling into question the efficacy and safety of phosphate binding in this population,
with normal phosphate concentration prior to initiation of binder treatment (Supplementary
Tables S19–24). In this analysis, all phosphate binders were analyzed collectively,
and the study was underpowered to detect differences between phosphate binders. Although
the data suggested that the observed increase in coronary artery calcification (CAC)
was mainly driven by the group treated with calcium-containing phosphate binders,
those treated with calcium-free binders had no advantage over placebo in terms of
progression of CAC. In addition, a well-executed mineral balance study in predialysis
patients using calcium-containing phosphate binders demonstrated the absence of any
effect on phosphate balance (while showing in the short term a positive calcium balance).
60
The second principal option to control phosphate in predialysis patients is dietary
restriction, as will be addressed in Recommendation 4.1.8. However, in both the NHANES
and MDRD cohorts that examined the general population and advanced CKD, respectively,
dietary intake or intervention to reduce dietary phosphate intake as assessed by either
urinary excretion or dietary recall had only minimal effects on serum phosphate.61,
62 It is unknown whether this minimal decline in serum phosphate concentrations or
the more robust lower phosphate intake translates into beneficial clinical outcome.
A subsequent analysis of the MDRD study found no impact of low phosphate intake as
compared with higher intake on cardiovascular disease or all-cause mortality.
63
It needs to be noted that in this study baseline phosphate levels were normal on average,
so results are possibly not applicable to CKD patients with progressively or persistently
elevated serum phosphate (see rationale for Recommendation 4.1.5).
Taken together, the key insights from these data were: (i) the association between
serum phosphate and clinical outcome is not monotonic; (ii) there is a lack of demonstrated
efficacy of phosphate binders for lowering serum phosphate in patients with CKD G3a
to G4; (iii) the safety of phosphate binders in this population is unproven; and (iv)
there is an absence of data showing that dietary phosphate restriction improves clinical
outcomes. Consequently, the Work Group has abandoned the previous suggestion to maintain
phosphate in the normal range, instead suggesting that treatment be focused on patients
with hyperphosphatemia. The Work Group recognizes that preventing, rather than treating,
hyperphosphatemia may be of value in patients with CKD G3a to G5D, but acknowledges
that current data are inadequate to support the safety or efficacy of such an approach
and encourages research in this specific area.
Only 2 RCTs have examined phosphate-lowering therapy in children with CKD or on dialysis;64,
65 due to the low number of patients and short follow-up, both studies did not meet
literature inclusion criteria set a priori together with the evidence review team
(ERT). The first RCT examined biochemical endpoints only and showed equivalent phosphate
control with calcium acetate and sevelamer hydrochloride in an 8-week cross-over trial.
65
In the second, 29 children were randomized to different combinations of phosphate
binders and vitamin D analogs; bone biopsies suggested that the sevelamer group had
reduced bone formation versus baseline at 8-month follow-up, but numbers were too
small for comparison versus the calcium carbonate–treated group.
64
Several studies in children on dialysis have shown an association between high phosphate
levels and increased vessel thickness,66, 67, 68 vessel stiffness68, 69 and CAC.67,
68, 70, 71 In young adults on dialysis, the CAC score was shown to double within 20
months, and progression was associated with higher serum phosphate levels.
71
Research recommendations
•
RCTs for controlling hyperphosphatemia in patients with CKD G3a to G5D, with appropriate
follow-up and power, should be conducted to assess various phosphate-lowering therapy
strategies for reducing the incidence of patient-level endpoints (e.g., CKD progression)
in children and adults.
•
RCTs of low and high dietary phosphate intake in patients in CKD G3a to G5 should
be conducted to test the hypothesis that high dietary phosphate intake increases cardiovascular
risk either directly or indirectly through induction of FGF23.
•
If the feasibility of a placebo-controlled trial is threatened due to perceived lack
of equipoise (i.e., “unethical” to not lower elevated serum phosphate levels, despite
the lack of high-quality data), a prospective trial comparing 2 different phosphate
targets in patients with CKD G3a to G5D is encouraged.
•
RCTs should be conducted in normophosphatemic CKD patients in order to test the hypothesis
that active compensatory mechanisms to counterbalance increased phosphate intake (such
as increases in FGF23 and PTH) are associated with poorer clinical outcome, despite
comparable serum phosphate concentration. Interventions could include dietary phosphate
restriction, phosphate-binder therapy, novel compounds to limit phosphate uptake,
or a combination thereof.
4.1.3: In adult patients with CKD G3a–G5D, we suggest avoiding hypercalcemia (2C).
In children with CKD G3a–G5D, we suggest maintaining serum calcium in the age-appropriate
normal range (2C).
Rationale
As is the case for phosphate, novel epidemiological evidence linking higher calcium
concentrations to increased mortality in adults with CKD has accumulated since the
2009 KDIGO CKD-MBD guideline (Supplementary Tables S49–S50, S52–S55).42, 43, 44, 47,
50, 60, 72, 73, 74 Moreover, and in addition to previous observations,
48
novel studies link higher concentrations of serum calcium to nonfatal cardiovascular
events.75, 76 This consistency justifies the change of this recommendation from 2D
to 2C, although the overall evidence base remains limited due to the lack of prospective
controlled trial data.
Hypocalcemia is a classical feature of untreated CKD, in part secondary to diminished
gastrointestinal (GI) uptake of calcium due to vitamin D deficiency.
77
Hypocalcemia contributes to the pathogenesis of secondary hyperparathyroidism (SHPT)
and renal osteodystrophy. Therefore, the previous recommendation suggested maintaining
serum calcium in the normal range, including the correction of hypocalcemia. A more
recent retrospective observational analysis of a large dialysis cohort confirmed the
association between hypocalcemia and mortality risk.
50
Two other recent observations, however, raised doubt within the KDIGO guideline Work
Group about the generalizability of the suggestion to correct hypocalcemia. The first
is the potential harm for some adults associated with a positive calcium balance (while
serum calcium levels do not necessarily reflect calcium balance).78, 79 The second
observation is that the prevalence of hypocalcemia may have increased after the introduction
of calcimimetics (cinacalcet) in patients on dialysis.38, 80, 81 The clinical implications
of this increased incidence of low calcium due to the therapeutic institution of a
calcimimetic is uncertain, but may be less harmful. With regard to the intention-to-treat
(ITT) population of the EVOLVE trial, no negative signals were associated with the
persistently low serum calcium levels in the cinacalcet arm of the trial. Retaining
the 2009 KDIGO Guideline on this issue would support the concept that patients developing
hypocalcemia during calcimimetic treatment require aggressive calcium treatment. Given
the unproven benefits of this treatment and the potential for harm, the Work Group
emphasizes an individualized approach to the treatment of hypocalcemia rather than
recommending the correction of hypocalcemia for all patients. However, significant
or symptomatic hypocalcemia should still be addressed. Symptomatic or severe hypocalcemia
may benefit from correction to prevent adverse consequences such as bone disease,
hyperparathyroidism, and QTc interval prolongation.
Childhood and adolescence are critical periods for bone mass accrual: in healthy children
the calcium content of the skeleton increases from ∼25 g at birth to ∼1000 g in adults,
and ∼25% of total skeletal mass is laid down during the 2-year interval of peak height
velocity.
82
The mean calcium accretion rate in healthy pubertal boys and girls peaks at 359 and
284 mg/d, respectively.
83
The updated evidence review identified a prospective cohort study in 170 children
and adolescents with CKD G2 to G5D (Supplementary Table S49–S50, S52–S55) that showed
that lower serum calcium levels were independently associated with lower cortical
volumetric BMD Z-scores.
19
Over 1 year of follow-up in 89 children, a change in the cortical BMD Z-score positively
correlated with baseline calcium (P = 0.008) and increase in calcium (P = 0.002) levels,
particularly in growing children. During the 1-year follow-up, 6.5% of children sustained
a fracture. Notably, a lower cortical BMD Z-score predicted future fractures: the
HR for fracture was 1.75 (95% CI: 1.15–2.67; P = 0.009) per SD decrease in baseline
BMD.
19
Thus, the Work Group recognizes the higher calcium requirements of the growing skeleton
and suggests that serum calcium levels are maintained in the age-appropriate normal
range in children and adolescents.
Research recommendations
•
Calcium balance study in dialysis patients should be pursued at baseline versus after
start of calcimimetic treatment (with and without calcium supplementation, adaptations
in dialysate calcium concentrations, and/or concomitant active vitamin D analog treatment).
•
RCTs in children and adolescents with CKD should be conducted to determine whether
calcium-based phosphate binders, as compared with calcium-free phosphate binders,
promote bone accrual (as measured by bone density and structure, and fractures), and
to determine the impact of phosphate binders on arterial calcification in the context
of the high calcium requirement of growing bones.
4.1.4: In patients with CKD G5D, we suggest using a dialysate calcium concentration
between 1.25 and 1.50 mmol/l (2.5 and 3.0 mEq/l) (2C).
Rationale
Based on the available evidence, the 2009 Work Group considered that a dialysate calcium
concentration of 1.25 mmol/l (2.5 mEq/l) would yield neutral calcium balance, but
this statement was subsequently challenged by kinetic modeling studies.
84
Two relevant new RCTs are available concerning this topic (Supplementary Tables S13–S18).85,
86 In the study by Spasovski et al.,
86
the effects of 2 different dialysate calcium concentrations were examined in patients
with adynamic bone disease, and the lower dialysate calcium (1.25 mmol/l [2.5 mEq/l])
was found to improve bone and mineral parameters compared with the higher concentration
of 1.75 mmol/l (3.5 mEq/l). Their data confirmed the results of previous papers and
also support individualization of dialysate calcium concentrations as recommended
previously by the Work Group. The comparator in this study, however, was a high dialysate
calcium concentration of 1.75 mmol/l (3.5 mEq/l), leaving open the possibility that
lower levels of dialysate calcium (>1.25 mmol/l [2.5 mEq/l] but <1.75 mmol/l [3.5
mEq/l]) would be equally beneficial. Ok et al. randomized 425 HD patients with iPTH
levels < 300 pg/ml (32 pmol/l) and baseline dialysate calcium concentrations between
1.5 and 1.75 mmol/l (3.0–3.5 mEq/l) to concentrations of either 1.25 mmol/l (2.5 mEq/l)
or 1.75 mmol/l (3.5 mEq/l).
85
Lowering dialysate calcium levels slowed the progression of CAC and improved biopsy-proven
bone turnover (low bone turnover decreased from 85.0% to 41.8%) in this cohort of
patients on HD. In this trial, the comparative effects of a 1.5 mmol/l (3.0 mEq/l)
calcium concentration were not addressed.
Retrospective observational data by Brunelli et al.
87
suggested safety concerns (i.e., heart failure events, hypotension) associated with
the default use of dialysate calcium concentrations < 1.25 mmol/l (2.5 mEq/l). Conversely,
at the high end of dialysate calcium concentration (1.75 mmol/l [3.5 mEq/l]), Kim
et al.
88
found increased risk for all-cause mortality and cardiovascular or infection-related
hospitalization in incident HD patients for high dialysate calcium. However, observational
studies, in general, may not be sufficient to warrant changes to treatment recommendations.
Patients with mild hypocalcemia might potentially even have a positive calcium mass
transfer when dialyzed against a concentration of 1.25 mmol/l (2.5 mEq/l), but no
such metabolic balance studies exist. Taken together, the Work Group felt that this
recommendation remains valid as written in 2009 and that there is no new evidence
justifying a change in the wording. However, additional studies of better quality
are now available, and as such the evidence grade has been upgraded from 2D to 2C.
Research recommendation
•
Calcium balance studies should be performed with non–calcium-containing versus calcium-containing
phosphate binders, and vitamin D sterols versus cinacalcet in different calcium dialysate
settings. These studies should include children and adolescents and assess calcium
balance in the context of skeletal calcium accrual.
4.1.5: In patients with CKD G3a–G5D, decisions about phosphate-lowering treatment
should be based on progressively or persistently elevated serum phosphate (Not Graded).
Rationale
With regard to 2017 Recommendation 4.1.5 (formerly 2009 Recommendation 4.1.4), the
previous 2009 KDIGO CKD-MBD guideline commented that available phosphate binders are
all effective in the treatment of hyperphosphatemia, and that there is evidence that
calcium-free binders may favor halting progression of vascular calcifications compared
with calcium-containing binders.
30
Concerns about calcium balance and uncertainties about phosphate lowering in CKD patients
not on dialysis, coupled with additional hard endpoint RCTs and a systematic review
(comparing effects on mortality for calcium-free vs. calcium-containing phosphate
binders), resulted in the decision to reevaluate this recommendation.
Based on new pathophysiological insights into phosphate regulation and the roles of
FGF23 and (soluble) Klotho in early CKD, clinical studies had been initiated investigating
phosphate-lowering therapies in CKD patients in whom hyperphosphatemia had not yet
developed. Here, the concept of early phosphate retention, possibly represented by increases
in FGF23 serum or plasma concentrations, was the focus of scientific attention. The
most notable RCT was performed by Block et al.
59
In this study, predialysis patients (CKD G3b–G4) with mean baseline serum phosphate
concentrations of 4.2 mg/dl (1.36 mmol/l) were exposed to 3 different phosphate binders
(sevelamer, lanthanum, or calcium acetate) versus matching placebos, in order to explore
effects on serum phosphate levels, urinary phosphate excretion, serum FGF23 levels,
vascular calcification, bone density, etc., with a 9-month follow-up (Supplementary
Tables S19–S24). While there was a small decrease in serum phosphate concentrations
(for those allocated to active treatment) and a 22% decrease in urinary phosphate
excretion (suggesting adherence to therapy), no differences in changes in FGF23 levels
were observed versus placebo, as already discussed in Recommendation 4.1.2. In contrast
to the authors’ expectations, progression of coronary and aortic calcification was
observed with active phosphate-binder treatment, while there was no progression in
the placebo arm. Subgroup analysis suggested that this negative effect was accounted
for by calcium acetate treatment, but neither calcium-free binders were superior to
placebo with regard to this surrogate endpoint.
This study was further supported by another metabolic study in a small group of patients
with CKD G3b to G4, in whom the addition of 3 × 500 mg calcium carbonate to meals
containing 1 g of calcium and 1.5 g of phosphorus per day did not affect baseline
neutral phosphate balance, but caused a significantly positive calcium balance,
60
at least in the short term. Due to its low number of patients and short duration,
this study did not fulfill the predefined inclusion criteria for full evidence review.
Nevertheless, in the Work Group’s opinion, this well-performed metabolic study may
present a plausible and relevant safety signal, and thus should be mentioned here.
Both Block et al.
59
and Hill et al.
60
studied subjects with essentially normal phosphate concentrations at baseline. Thus,
there may be 2 key messages from these studies. First, normophosphatemia may not be
an indication to start phosphate-lowering treatments. Second, the concept that not
all phosphate binders are interchangeable must be noted. Whether disproportional elevations
in FGF23 serum concentrations may become a signal in order to start phosphate-lowering
therapies in early CKD will need to be investigated in appropriate trial settings.
Considering these insights, especially regarding CKD patients not on dialysis, and
as already suggested in the rationale of Recommendation 4.1.2, the Work Group felt
that the updated guideline should clarify that phosphate-lowering therapies may only
be indicated in the event of “progressive or persistent hyperphosphatemia,” and not
to prevent hyperphosphatemia. When thinking about risk-benefit ratios, even calcium-free
binders may possess a potential for harm (e.g., due to side effects such as GI distress
and binding of essential nutrients). The broader term “phosphate-lowering therapies”
instead of phosphate-binding agents was introduced, because all possible approaches
(i.e., binders, diet, and dialysis) can be effective and because phosphate transport
inhibitors may expand the therapeutic armamentarium in the not-so-distant future.
There have been no additional data since 2008 with regard to “safe” phosphate level
thresholds or hard endpoints (i.e., mortality, cardiovascular events, and progression
of CKD) from RCTs treating patients toward different phosphate (or FGF23) targets.
The previous qualifiers (presence of other components of CKD-MBD, concomitant therapies,
side effect profile) were deleted because the Work Group thought that their consideration
was self-evident. Diurnal variation of serum phosphate concentrations was discussed
as another pathophysiologically relevant aspect of evaluation. While it was felt that
these variations in daily phosphate levels do affect the accuracy of evaluations,
the notion of variable timing for blood sampling was considered unfeasible in clinical
routine practice and therefore not included in the guideline text.
Research recommendations
•
Prospective clinical trials studying the value of levels of FGF23 (and possibly soluble
Klotho) as indicators for establishing phosphate-lowering therapies should be undertaken;
desirable endpoints should include: CKD progression, cardiovascular calcification,
cardiovascular events, and mortality.
•
See research recommendations following Recommendation 4.1.2.
4.1.6: In adult patients with CKD G3a–G5D receiving phosphate-lowering treatment,
we suggest restricting the dose of calcium-based phosphate binders (2B). In children
with CKD G3a–G5D, it is reasonable to base the choice of phosphate-lowering treatment
on serum calcium levels (Not Graded).
Rationale
The Work Group thought that the new available data and the changes applied to 2009
Recommendation 4.1.4 (now Recommendation 4.1.5) suggested a need to revise the 2009
Recommendation 4.1.5 (now Recommendation 4.1.6). The balance study by Hill et al.
60
supported results reported by Spiegel and Brady
79
in normophosphatemic adults with CKD G3b to G4, which suggested potential harms of
liberal calcium exposure in such cohorts, but due to their study designs were not
eligible for full evidence review by the ERT. The RCT by Block et al.
59
in a much larger, similar cohort and 2 additional RCTs in hyperphosphatemic CKD patients
have added hard endpoint data when prospectively comparing the calcium-free binders,
mostly sevelamer, with calcium-containing binders in predialysis or dialysis adult
patients, respectively (Supplementary Tables S19–S24)59, 89, 90 These results were
also supported by results from recent systematic reviews;91, 92, 93, 94 however, because
the evidence review team (ERT) had considered all included studies separately and
individually during this update process, these meta-analyses did not have additional
bearing on the decision making by the Work Group.
Overall, the Work Group determined that there is new evidence suggesting that excess
exposure to calcium through diet, medications, or dialysate may be harmful across
all GFR categories of CKD, regardless of whether other candidate markers of risk such
as hypercalcemia, arterial calcification, adynamic bone disease, or low PTH levels
are also present. Therefore, these previous qualifiers in the 2009 KDIGO recommendation
were deleted, acknowledging that they may still be valid in high-risk scenarios.
Di Iorio et al. reported RCTs in both predialysis and dialysis patients showing significant
survival benefits over a 3-year interval for patients treated with sevelamer versus
calcium-containing binders (Supplementary Tables S19–S24).89, 90 Both studies were
analyzed by the ERT and were graded as relevant RCTs with a moderate risk of bias
(Supplementary Tables S23 and S24), leading to a 2B recommendation. Overall, the findings
from all identified studies seemed to show either a potential for benefit or an absence
of harm associated with calcium-free phosphate-binding agents to treat hyperphosphatemia
compared with calcium-based agents (Supplementary Tables S20 and S21).
The wording in Recommendation 4.1.6 of “restricting the dose of calcium-based phosphate
binders” was retained from previous 2009 Recommendation 4.1.5; however, the qualifier
that the recommendation applies to patients with persistent or recurrent hypercalcemia
was removed. Given the fact of 2 reasonably large RCTs demonstrating mortality risks
associated with calcium-containing binder treatment, it was debated within the Work
Group whether the recommendation should be stronger, possibly using “avoid” instead
of “restrict.” However, some members of the Work Group felt that available evidence
does not conclusively demonstrate that calcium-free agents are superior to calcium-based
agents. In addition, none of the studies provided sufficient dose threshold information
about calcium exposure, nor did they give information on the safety of moderately
dosed calcium-containing binders in combination therapies. Finally, because KDIGO
guidelines are intended for a global audience and calcium-free agents are not available
or affordable in all jurisdictions, recommending against the use of calcium-based
binders would imply that no treatment is preferable to using calcium-based agents.
Despite the understandable clinical desire to have numeric targets and limits, the
Work Group could not make an explicit recommendation about a maximum dose of calcium-based
binders, preferring to leave this to the judgment of individual physicians while acknowledging
the potential existence of a safe upper limit of calcium dose. Of note, 2 short-term
studies in stable CKD patients not on dialysis found that positive calcium balance
may occur with total intakes as low as 800 and 1000 mg/d, respectively.60, 79 Such
short-terms results are informative but not conclusive, and decisions must be individualized
for each patient.
The recent availability of iron-containing phosphate binders was discussed within
the Work Group but did not affect the recommendations given the absence of data on
long-term patient-centered outcomes in the published phase 3 trials.95, 96, 97
All of the above studies were limited to adults. Importantly, concerns regarding the
adverse effects of excess exposure to calcium through diet, medications, or dialysate
may not be generalizable to children. Skeletal growth and development are characterized
by rapid calcium accrual,
83
as described in Recommendation 4.1.3. Furthermore, recent studies demonstrated that
bone accrual continues into the third decade of life in healthy individuals, well
beyond cessation of linear growth.98, 99 Of relevance to adolescents with CKD, bone
accrual between ages 18 and 24 was especially pronounced among those with late puberty.
100
Therefore, studies of calcium- and non–calcium-containing binders and other therapies
that impact calcium balance should consider the needs of the developing skeleton.
The observation that serum calcium levels were positively associated with increases
in BMD in children with CKD, and that this association was significantly more pronounced
with greater linear growth velocity,
19
illustrates the unique needs of the growing skeleton (see Recommendation 4.1.3). Lastly,
a recent prospective cohort study in 537 children with predialysis CKD demonstrated
that phosphate-binder treatment (calcium-based in 82%) was associated with decreased
risk of incident fractures (HR: 0.37, 95% CI: 0.15–0.91), independent of age, sex,
eGFR, and PTH levels.
101
Although this study did not meet the criteria for inclusion in the evidence review,
it highlights the need for additional studies in children. There is a lack of data
suggesting adverse effects of excess exposure to calcium through diet, medications
or dialysate in children. The Work Group concluded that there was insufficient evidence
to change this recommendation in children, who may be uniquely vulnerable to calcium
restriction.
Research recommendations
•
Calcium and phosphate balance studies should be conducted using different calcium-based
binder doses and combinations with calcium-free binders in hyperphosphatemic patients
across all GFR categories of CKD.
•
RCTs assessing the effect of iron-based phosphate binders on patient-centered and
surrogate outcomes across all GFR categories of CKD should be undertaken; comparators
should be placebo, calcium-based binders, or other calcium-free binders.
•
RCTs using phosphate transport inhibitors (e.g., nicotinamide,
102
tenapanor
103
) as “add-on” treatments in patients with resistant hyperphosphatemia should be investigated.
•
Prospective clinical and balance studies should examine the role of magnesium as a
phosphate binder, with regard to patient-centered outcomes, calcification, and cardiovascular
event rates.
•
RCTs in children and adolescents with CKD should be conducted to determine whether
calcium-based phosphate binders, as compared with calcium-free phosphate binders,
promote bone accrual (as measured by bone density and structure, and fractures), and
to determine the impact of phosphate binders on arterial calcification in the context
of the high calcium requirement of growing bones.
4.1.8: In patients with CKD G3a–G5D, we suggest limiting dietary phosphate intake
in the treatment of hyperphosphatemia alone or in combination with other treatments
(2D). It is reasonable to consider phosphate source (e.g., animal, vegetable, additives)
in making dietary recommendations (Not Graded).
Rationale
There was no general controversy toward the 2009 KDIGO CKD-MBD Guideline on dietary
phosphate restriction as an important standard of practice to lower elevated phosphate
levels, but previous 2009 recommendation 4.1.7 (now 4.1.8) on limiting dietary phosphate
intake was considered vague, especially with regard to new evidence on different phosphate
and phosphoprotein sources. Within this guideline update, predefined criteria on study
duration and cohort size prohibited inclusion of some study reports for full evidence
review. Nevertheless, the Work Group felt that some of these reports presented safety
signals demanding a brief discussion.
As summarized in Supplementary Tables S25–S30, only 2 studies on this topic in dialysis
patients fulfilled the evidence review criteria.104, 105 Both studies investigated
the impact of intensified versus routine dietary counseling on serum phosphate levels
after a follow-up of 6 months. In both studies, the intensified counseling groups
more successfully reached the laboratory targets; however, no hard endpoints were
documented. Accordingly, the quality of evidence for outcome was rated as very low.
Similarly, a recent Cochrane review concluded that there is low-quality evidence that
dietary interventions positively affect CKD-MBD biomarkers.
106
The daily phosphate intake for a typical American diet varies with age and gender.
A majority of young to middle-aged men take in more than 1600 mg/d, whereas women
in the same age groups take in about 1000 mg/d.
107
On a global scale, there are quite significant differences in diet compositions to
be considered. Estimates of dietary phosphate from food composition tables likely
underestimate the phosphate content because they may mostly reflect the “natural”
phosphate content of foods that are highest (e.g., dairy products, meats, poultry,
fish, and grains). There are actually 3 major sources of phosphates: natural phosphates
(as cellular and protein constituents) contained in raw or unprocessed foods, phosphates
added to foods during processing, and phosphates in dietary supplements/medications.
Russo et al.
108
assessed the effect of dietary phosphate restriction on the progression of CAC. This
study was not designed to compare the efficacy of phosphate binders against dietary
phosphate restriction. However, they found that dietary phosphate restriction alone
did not lead to a decrease in urinary phosphate excretion, nor did it prevent progression
of CAC. However, the urine data cast doubt on compliance with the diet, and there
was no control group on a normal or high-phosphate diet.
Aggressive dietary phosphate restriction is difficult because it has the potential
to compromise adequate intake of other nutrients, especially protein. Zeller et al.
109
showed that the restriction of dietary protein and phosphate could be achieved with
maintenance of good nutrition status with intense counseling. They demonstrated that
dietary protein/phosphate restriction resulted in a significant reduction in urinary
phosphate excretion when compared with a control diet.
Dietary supplements and over-the-counter or prescription medications are hidden sources
of phosphate. They may contain phosphate salts within their inactive ingredients.
The data on the amount of phosphate in oral medications and vitamin/mineral supplements
is limited, but they have the potential to contribute significantly to the phosphate
load considering the number of medications CKD patients are required to take.110,
111
Another consideration for modification of dietary phosphate and control of serum phosphate
is the “bioavailability” of phosphorus in different foods based on the form—organic
versus inorganic sources of phosphate. Animal- and plant-based foods contain the organic
form of phosphate. Food additives contain inorganic phosphate. About 40% to 60% of
animal-based phosphate is absorbed, depending on the GI vitamin D receptor activations.
Plant phosphate, mostly associated with phytates, is less absorbable (generally 20%–50%)
in the human GI tract. It behooves the dietitian and other interdisciplinary staff
to include education about the best food choices as they relate to absorbable phosphate.
Additionally, it is important for patients to be guided toward fresh and homemade
foods rather than processed foods in order to avoid additives.
Organic phosphate in such plant foods as seeds and legumes is less bioavailable because
of limited GI absorption of phytate-based phosphorus. In this context, Moe et al.
35
recently demonstrated that a vegetable-based diet showed significantly lower phosphate
absorption versus a meat-based diet with similar phosphate content. Inorganic phosphate
is more readily absorbed, and its presence in additive-laden processed, preserved,
or enhanced foods or soft drinks is likely to be underreported in nutrient databases.
Hence, the phosphate burden from food additives is disproportionately high relative
to natural sources that are derived from organic (animal and vegetable) food proteins,
and these additives are almost completely absorbed in the GI tract. For example, Benini
et al. showed that foods that contain phosphate additives have a phosphorus content
nearly 70% higher than those that do not contain additives.
112
Sherman and Mehta also demonstrated that phosphate contents between unprocessed and
processed meat or poultry may differ by more than 60%, and thus the absorbable phosphate
may even be 2 to 3 times higher per weight in processed food.
113
In contrast, many of the foods that are traditionally labeled as high phosphorus may
be more acceptable with the knowledge that the phosphorus is absorbed more slowly
and not as efficiently. For example, beans and nuts have always been listed as very
high in phosphorus; however, considering their lower absorption rate, they may be
acceptable as protein sources, if they are not too high in other nutrients such as
potassium.
The amount of phosphorus contributed by food intake is increasing with current and
new processing practices that utilize phosphorus-containing ingredients, including
popular foods such as restructured meats (formed, pressed, rolled, and shaped for
ease of preparation and ingestion), processed and spreadable cheeses, “instant” products
(puddings, sauces), frozen breaded products, and soft drinks.
114
Phosphate additives are also widely used in fast foods and convenience foods that
are fully or partially pre-made or instant.
110
Various types of nutrition education have had mixed results for control of serum phosphate.
Intense education focusing on phosphate intake has been useful to reduce retention
in some studies.105, 115 A simple education tool on how to read food labels and “look
for PHOS” (the study acronym) was successful in helping dialysis patients reduce their
phosphate intake. A magnifying glass was provided to help patients read labels,
116
as well as instructions available to guide “better choices” in fast-food restaurants.
Other studies have had less favorable results.
117
Taken together, these insights led the Work Group to the decision to not change the
principal recommendation, but to add a qualifier statement suggesting that phosphate
sources should be better substantiated and patient education should focus on best
choices. Finally, it must be emphasized that efforts to restrict dietary phosphate
must not compromise adequate protein intake.
Research recommendations
•
RCTs comparing low, medium, and high phosphate intake on phosphate metabolism and
homeostasis, including responses concerning FGF23, PTH, calcification, and CKD progression,
in patients in CKD G3b to G4, should be performed.
•
In such study designs, the role of the phosphate quality should be studied: vegetable
versus meat versus additive sources.
•
Kinetic and balance studies on the uptake of phosphate additives in dialysis patients
should be performed.
•
Prospective trials identifying the most effective phosphate-lowering approach (benefit-risk-cost
ratio) should be performed across all CKD GFR categories—such as how best to combine
phosphate binders, phosphate transport inhibitors and diet (plus dialysis treatment
in CKD G5D)—with appropriate patient-centered and surrogate endpoints in mind (e.g.,
calcification, FGF23 levels, and LVH).
Chapter 4.2: Treatment of abnormal PTH levels in CKD-MBD
4.2.1: In patients with CKD G3a–G5 not on dialysis, the optimal PTH level is not known.
However, we suggest that patients with levels of intact PTH progressively rising or
persistently above the upper normal limit for the assay be evaluated for modifiable
factors, including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin
D deficiency (2C).
Rationale
The pathogenesis of SHPT is complex and driven by several factors, including vitamin
D deficiency, hypocalcemia, and hyperphosphatemia. Elevated FGF23 concentrations exacerbate
SHPT through further reductions in 1,25(OH)2 vitamin D (calcitriol) levels. Calcitriol
deficiency results in decreased intestinal absorption of calcium and may lead to hypocalcemia,
a major stimulus for PTH secretion. This leads to parathyroid cell proliferation,
contributing to SHPT. The incidence and severity of SHPT increases as kidney function
declines and can lead to significant abnormalities in bone mineralization and turnover.
The 2009 KDIGO CKD-MBD Guideline recommended addressing modifiable risk factors for
all patients with a PTH level above the upper limit of normal for the assay used.
30
Unfortunately, there is still an absence of RCTs that define an optimal PTH level
for patients with CKD G3a to G5, or clinical endpoints of hospitalization, fracture,
or mortality. The Work Group felt that modest increases in PTH may represent an appropriate
adaptive response to declining kidney function, due to its phosphaturic effects and
increasing bone resistance to PTH,
118
and have revised this statement to include “persistently” above the upper normal PTH
level as well as “progressively rising” PTH levels, rather than simply “above the
upper normal limit” as in the 2009 KDIGO Guideline. Thus, treatment should not be
based on a single elevated value.
Although the optimal PTH is not known, the Work Group felt that rising PTH levels
in CKD G3a-G5 warrant examination of modifiable factors, such as vitamin D insufficiency
or deficiency, hypocalcemia, and hyperphosphatemia. In the interval since the 2009
KDIGO Guideline, 1 eligible RCT examined the impact of cholecalciferol supplementation
(Supplementary Table S31) and 3 examined the impact of phosphate binders on PTH levels
in the nondialysis CKD population. Oksa et al.
119
reported an RCT of a high (20,000 international units [IU]/wk) versus low (5,000 IU/wk)
dose of cholecalciferol supplementation in 87 adults with CKD G2 to G4 (Supplementary
Tables S31–S36). Serum 25(OH) vitamin D levels increased significantly in both groups
and were significantly greater in the high-dose arm at the completion of the 12-month
intervention. PTH levels decreased significantly in both groups; however, the PTH
levels did not differ significantly between groups at the completion of the study.
In this context, Recommendation 3.1.3 on native vitamin D supplementation remains
valid from the previous 2009 guideline publication.
Three recent RCTs in the nondialysis CKD population evaluated phosphate binders and
their effects on surrogate endpoints, such as vascular calcification, arterial compliance,
left ventricular mass, and BMD, as well as calcium, phosphate, and PTH levels. Two
RCTs compared sevelamer with placebo (Supplementary Tables S31–S36), the first in
109 nondiabetic CKD G3a to G3b patients
120
and the second in 117 CKD patients with a mean eGFR of 36 ± 17 ml/min/1.73 m2.
121
The studies were conducted over 36 weeks and 24 months, respectively, and neither
study demonstrated significant differences in PTH levels between sevelamer and placebo
groups. Another RCT involving 148 CKD patients (eGFR: 20–45 ml/min/1.73 m2) compared
placebo with 3 different phosphate binders (calcium-based, lanthanum, and sevelamer)
over a 9-month period and reported that PTH levels remained stable in those on active
therapy (combined phosphate-binder groups) but increased by 21% in the placebo group
(P = 0.002)
59
(Supplementary Table S33).
In the updated recommendation, an additional modifiable risk factor, “high phosphate
intake,” was added because of the increasing recognition that excess phosphate intake
does not always result in hyperphosphatemia, especially in early CKD, and that high
phosphate intake may promote SHPT. While dietary phosphate, whether from food or additives,
is modifiable, better methods for assessment of dietary phosphate intake are required.
4.2.2: In adult patients with CKD G3a–G5 not on dialysis, we suggest that calcitriol
and vitamin D analogs not be routinely used (2C). It is reasonable to reserve the
use of calcitriol and vitamin D analogs for patients with CKD G4–G5 with severe and
progressive hyperparathyroidism (Not Graded).
In children, calcitriol and vitamin D analogs may be considered to maintain serum
calcium levels in the age-appropriate normal range (Not Graded).
Rationale
Prevention and treatment of SHPT is important because imbalances in mineral metabolism
are associated with CKD-MBD and higher PTH levels are associated with increased morbidity
and mortality in CKD patients. Calcitriol and other vitamin D analogs have been the
mainstay of treatment of SHPT in individuals with CKD for many decades. The 2009 KDIGO
CKD-MBD Guideline summarized multiple studies demonstrating that administration of
calcitriol or vitamin D analogs (such as paricalcitol, doxercalciferol, and alfacalcidol)
resulted in suppression of PTH levels.
30
However, there was a notable lack of trials demonstrating improvements in patient-centered
outcomes.
Multiple well-conducted RCTs cited in the 2009 guideline reported benefits of calcitriol
or vitamin D analogs in treating SHPT in patients with CKD G3a to G5; 2 primarily
involved biochemical endpoints,122, 123 and 2 evaluated bone histomorphometry.124,
125 Despite the lack of hard clinical endpoints, these data led to the original recommendation
to treat elevated PTH with calcitriol or vitamin D analogs early in CKD to prevent
parathyroid hyperplasia and its skeletal consequences (2C). Although benefits were
predominantly related to suppression of SHPT, adverse effects of hypercalcemia were
noted to be of concern in the 2009 KDIGO CKD-MBD Guideline.
30
The effects of vitamin D therapy on biochemical endpoints in CKD have been previously
documented, especially with regard to reduced PTH levels. Numerous previous studies
have reported significant reductions of PTH levels with calcitriol or vitamin D analogs
in CKD G3a to G3b and G4 when compared with placebo123, 125, 126 and recent RCTs have
also demonstrated that vitamin D treatment effectively lowers PTH levels in CKD G3a
to G5.127, 128
Additional RCTs of calcitriol or vitamin D analog therapy have been published since
the 2009 KDIGO CKD-MBD Guideline (Supplementary Tables S37–S42). Two, in particular,
demonstrated a significantly increased risk of hypercalcemia in patients treated with
paricalcitol, compared with placebo, in the absence of beneficial effects on surrogate
cardiac endpoints, as detailed below.127, 128 These results, combined with the opinion
that moderate PTH elevations may represent an appropriate adaptive response, led the
Work Group to conclude that the risk-benefit ratio of treating moderate PTH elevations
was no longer favorable and that the use of calcitriol or vitamin D analogs should
be reserved for only severe and progressive SHPT.
The 2 recent RCTs were designed to detect potential benefits of calcitriol or vitamin
D analogs on cardiac structure and function, as measured by magnetic resonance imaging
(MRI), in adults with CKD (Supplementary Tables S37–S42). The rationale for these
studies is that calcitriol and vitamin D analogs act through the vitamin D receptor
(VDR) to exert their benefits to inhibit PTH secretion, and the VDR is also present
in many tissues and organs including vascular smooth muscle, endothelial cells, and
the heart. The key evidence for changes in Recommendation 4.2.2 predominantly came
from these trials.
The first study was a double-blind RCT by Thadhani et al. (the PRIMO study), where
participants with CKD G3a to G4, mild to moderate LVH, and PTH levels between 50 and
300 pg/ml (5.3–32 pmol/l) were assigned to placebo (n = 112) or paricalcitol (n =
115) to test the primary hypothesis that paricalcitol will reduce left ventricular
mass index (LVMI) over a 48-week interval.
128
Paricalcitol was administered at a dose of 2 μg/d, with protocol-specified dose reduction
to 1 μg/d, if the serum calcium was > 11 mg/dl (2.75 mmol/l). Baseline PTH levels
were approximately 1.5 times the upper limit of normal. The ITT analysis revealed
that paricalcitol did not reduce LVMI, nor did it modify diastolic function. Of subjects
on paricalcitol, the mean serum calcium increased by 0.32 mg/dl (0.08 mmol/l) (95%
CI: 0.19–0.45 mg/dl; 0.05–0.11 mmol/l) versus a decrease by 0.25 mg/dl (0.06 mmol/l)
(95% CI: −0.37 to −0.12 mg/dl; −0.09 to –0.03 mmol/l) in the placebo group. Hypercalcemia
was defined as 2 consecutive measurements of serum calcium > 10.5 mg/dl (> 2.63 mmol/l),
and the number of patients requiring dose reductions from 2 μg/d to 1 μg/d and episodes
of hypercalcemia were more common in the paricalcitol group (22.6%) compared with
the placebo (0.9%) group.
In the second key study, a double-blind RCT by Wang et al. (the OPERA study), subjects
with CKD G3a to G5, LVH, and PTH ≥ 55 pg/ml (5.83 pmol/l) were randomly assigned to
receive paricalcitol (n = 30) or placebo (n = 30).
127
The primary endpoint was change in LVMI over 52 weeks. Baseline PTH levels were approximately
twice the upper limit of normal. Change in LVMI did not differ significantly between
groups, nor did secondary outcomes such as measures of systolic and diastolic function.
The median (interquartile range) changes in serum calcium were 0.08 mmol/l (0.32 mg/dl)
(95% CI: 0.02–0.16 mmol/l; 0.08–0.64 mg/dl) and 0.01 mmol/l (0.04 mg/dl) (95% CI:
–0.06 to 0.05 mmol/l; –0.24 to 0.2 mg/dl) in the paricalcitol and placebo arms, respectively.
Hypercalcemia, defined as any serum calcium > 2.55 mmol/l (> 10.2 mg/dl), occurred
in 43.3% and 3.3% of participants in the paricalcitol and placebo arms, respectively.
Of note, 70% of those who were hypercalcemic received concomitant calcium-based phosphate
binders. Generally the hypercalcemia was mild and could be corrected by stopping the
binder without changing the paricalcitol dose.
Recent meta-analyses were largely confirmatory and supported the hypercalcemia risk
association with calcitriol and vitamin D analogs.129, 130
The evidence review identified 2 RCTs comparing paricalcitol with calcitriol (Supplementary
Tables S37–S42); neither demonstrated differences in the incidence of hypercalcemia.131,
132 Coyne et al.
131
compared calcitriol (0.25 μg/d) with paricalcitol (1 μg/d) in 110 patients with CKD
G3a to G3b and G4 and PTH > 120 pg/ml (12.7 pmol/l). The change in PTH was comparable
in the 2 arms (a decline of 52% vs. 46%) over the 6-month trial, and the incidence
of hypercalcemia was very low in both groups (only 3 with paricalcitol and 1 with
calcitriol). Further details regarding changes in biochemical parameters are provided
in Supplementary Tables S37–S42.
An alternative to calcitriol and its analogs is “nutritional” vitamin D supplementation
(cholecalciferol and ergocalciferol), which can also suppress PTH (especially in CKD
G3a–G3b) and decrease hypercalcemia because the normal homeostatic loops that suppress
the CYP27B remain intact. However, no studies of sufficient duration were identified
in this evidence review, and thus this therapy remains unproven.
Several studies have assessed the effect of PTH-lowering comparing nutritional vitamin
D supplements and calcitriol or vitamin D analogs.133, 134 However, these studies
were not identified in this evidence review because of their short duration.
The use of extended-release calcifediol, a novel vitamin D prohormone, to correct
low serum 25(OH) vitamin D levels and lower PTH has also been recently studied. This
agent reduces the catabolism of both 25(OH) vitamin D and 1,25(OH)2 vitamin D and
increases levels of both. An RCT of 429 patients with CKD G3a to G3b and G4 published
after our guideline systematic review reported at least a 10% reduction of intact
PTH levels in 72% of participants after 12 months, with no significant impact on calcium,
phosphate, or FGF23 levels.
135
No patient-level outcomes were reported, and thus this study did not impact the current
recommendation.
All of the above studies were conducted in adults. A recent Cochrane review examined
vitamin D therapy for bone disease in children with CKD G2 to G5 on dialysis.
136
Bone disease, as assessed by changes in PTH levels, was improved by all vitamin D
preparations regardless of route or frequency of administration. The prospective cohort
study demonstrated that high PTH levels were independently associated with reduced
cortical BMD Z-scores at baseline (P = 0.002) and 1-year follow-up (P < 0.001).
19
High PTH levels are associated with CAC in children on dialysis.67, 68 The Cochrane
review has not shown any significant difference in hypercalcemia risk with vitamin
D preparations compared with placebo, but 1 study showed a significantly greater risk
of hypercalcemia with i.v. calcitriol administration.
136
No difference in growth rates was detected between different vitamin D analogs or
use of oral or i.v. vitamin D treatments.
136
As noted in Recommendation 4.1.3, the Work Group recommended that serum calcium should
be maintained within age-appropriate reference range in children, and given the association
of high PTH levels with reduced bone mineralization and increased vascular calcification,
children are likely to require calcitriol or other active vitamin D analog therapy.
In summary, the PRIMO and OPERA studies failed to demonstrate improvements in clinically
relevant outcomes but demonstrated increased risk of hypercalcemia. Accordingly, the
guideline no longer recommends routine use of calcitriol or its analogs in CKD G3a
to G5. This was not a uniform consensus among the Work Group. It should be noted that
the participants in the PRIMO and OPERA trials only had moderately increased PTH levels,
thus therapy with calcitriol and vitamin D analogs may be considered in those with
progressive and severe SHPT.
There are still no RCTs demonstrating beneficial effects of calcitriol or vitamin
D analogs on patient-level outcomes, such as cardiac events or mortality, and the
optimal level of PTH in CKD G3a to G5 is not known. Furthermore, therapy with these
agents may have additional harmful effects related to increases in serum phosphate
and FGF23 levels. If initiated for severe and progressive SHPT, calcitriol or vitamin
D analogs should be started with low doses, independent of the initial PTH concentration,
and then titrated based on the PTH response. Hypercalcemia should be avoided.
Research recommendation
•
Multicenter RCTs should be conducted in children and adults to determine the benefits
or harms of calcitriol or vitamin D analogs in patients with CKD G3a to G5; patient-level
outcomes including falls, fractures, sarcopenia, muscle strength, physical function,
progression to end-stage kidney disease, cardiovascular events, hospitalizations,
and mortality should be assessed. Additional important patient-level outcomes to include
are bone pain, pruritus, and health-related quality of life. Studies should also include
patients with more severe SHPT and should determine the impact of reducing PTH to
different target levels, such as the normal range versus higher levels.
4.2.4: In patients with CKD G5D requiring PTH-lowering therapy, we suggest calcimimetics,
calcitriol, or vitamin D analogs, or a combination of calcimimetics with calcitriol
or vitamin D analogs
(2B).
Rationale
New data published since the 2013 KDIGO Madrid Controversies Conference prompted the
Work Group to reappraise the use of PTH-lowering therapies in patients with CKD G5D.
As shown in Supplementary Table S43, the ERT identified 2 new trials evaluating treatment
with cinacalcet versus placebo and 1 new trial evaluating calcitriol versus a vitamin
D analog. One open-label clinical trial was conducted evaluating the effect of cinacalcet
on bone histomorphometry.
145
There are still no new trials of calcitriol or vitamin D analogs that demonstrated
clear benefits in patient-level outcomes.
The Work Group discussed the EVOLVE trial at length. EVOLVE evaluated the effect of
cinacalcet versus placebo on patient-level outcomes in 3883 HD patients using a composite
endpoint of all-cause mortality, nonfatal myocardial infarction, hospitalization for
unstable angina, congestive heart failure, and peripheral vascular events. Secondary
endpoints included individual components of the primary endpoint, clinical fracture,
stroke, parathyroidectomy, and cardiovascular events and cardiovascular death.
38
The results of EVOLVE have proven controversial. The unadjusted primary composite
endpoint showed a nonsignificant reduction (HR: 0.93; P = 0.112) with cinacalcet use.
However, analyses adjusted for imbalances in baseline characteristics demonstrated
a nominally significant reduction in the primary composite endpoint (HR: 0.88; P =
0.008), as did sensitivity analyses accounting for patient nonadherence to randomized
study medication (HR: 0.77; 95% CI: 0.70–0.92)
137
or when patients were censored at the time of kidney transplant, parathyroidectomy,
or the use of commercial cinacalcet (HR: 0.84; P ≤ 0.001).
38
Further challenging the interpretation of the nonsignificant reduction in risk seen
with the unadjusted primary endpoint was a significant treatment-age interaction (P =
0.03),
38
leading to speculation that cinacalcet may be effective predominantly in older dialysis
patients. Approximately one-third of the EVOLVE participants were under the age of
55, and prespecified analyses that evaluated subjects above or below age 65 demonstrated
a significant reduction in risk associated with use of cinacalcet for both the primary
endpoint (HR: 0.74; P ≤ 0.001) and all-cause mortality (HR: 0.73; P ≤ 0.001) for those
aged above 65.
138
The Work Group also considered additional prespecified and post hoc analyses from
EVOLVE. These included a demonstrated significant reduction in the risk of severe
unremitting SHPT (defined by the persistence of markedly elevated PTH concentrations
[2 consecutive PTH values over 1000 pg/ml (106 pmol/l)] together with hypercalcemia
[serum calcium > 10.5 mg/dl (2.63 mmol/l)] or parathyroidectomy). Cinacalcet appeared
to consistently reduce the risk of this endpoint regardless of baseline PTH (HR: 0.31,
P ≤ 0.001 for those with baseline PTH 300–600 pg/ml [32–64 pmol/l]; HR: 0.49, P ≤
0.001 for those with baseline PTH 600–900 pg/ml [64–95 pmol/l]; HR: 0.41, P < 0.001
for those with PTH > 900 pg/ml [95 pmol/l]).
139
Cinacalcet had no effect on the risk of clinical fractures in unadjusted analyses
(HR: 0.93; P = 0.111) and showed a nominally significant reduction in risk of fracture
when adjusted for age (HR: 0.88; P = 0.007).
140
Thus, EVOLVE did not meet its primary endpoint that cinacalcet reduces the risk of
death or clinically important vascular events in CKD G5D patients. However, the results
of secondary analyses suggest that cinacalcet may be beneficial in this population
or a subset. There was a lack of uniform consensus among the Work Group members in
their interpretation of these data with regard to establishing cinacalcet as the recommended
first-line therapy for patients with CKD G5D requiring PTH-lowering therapy. While
some felt that only the primary analysis should be used to interpret the outcome,
others were equally convinced that the secondary analyses strongly suggested a benefit
of treatment with cinacalcet on important patient-level outcomes.
Despite these differences in interpretation, there was agreement among Work Group
members that the higher cost of cinacalcet was also a relevant consideration given
its uncertain clinical benefits. There was also agreement that the documented association
between good clinical outcomes and the extent of FGF23 reduction with cinacalcet warrants
further study.
141
No trials demonstrated the benefits of combination therapy (cinacalcet plus another
agent) on clinically relevant outcomes. However, several additional RCTs were identified
that studied the effect of combination therapy on putative surrogate outcomes (summarized
in Supplementary Tables S43–S48). Two trials evaluated the use of cinacalcet with
low-dose active vitamin D versus standard therapy. Urena-Torres et al.
142
demonstrated improved PTH-lowering efficacy in subjects treated with cinacalcet or
low-dose active vitamin D, while Raggi et al.
143
found that cinacalcet with low-dose vitamin D attenuated the progression of coronary
artery calcium accumulation when assessed using calcium volume scores (P = 0.009)
although not when using the more common Agatston score (P = 0.07). Two open-label
trials of cinacalcet were considered important in reaching consensus for Recommendation
4.2.4. The PARADIGM trial compared a cinacalcet-based treatment strategy with an active
vitamin D–based strategy in 312 HD patients and demonstrated similar reductions in
PTH in both treatment arms.
144
The BONAFIDE trial evaluated bone histomorphometry in 77 paired bone biopsy samples
in cinacalcet-treated subjects with proven high-turnover bone disease and demonstrated
reductions in bone formation rates and substantial increase in the number of subjects
with normal bone histology (from 0 at baseline to 20 after 6–12 months of therapy).
145
Two subjects developed adynamic bone disease, both of whom had PTH values < 150 pg/ml
(16 pmol/l), and 1 patient developed osteomalacia coincident with hypophosphatemia.
Despite being a prospective interventional trial, the BONAFIDE trial did not fulfill
our literature inclusion criteria, because there was no control group and only longitudinal
assessments were available, and thus is not listed in the Supplementary Tables.
It was recognized by the Work Group that newer, i.v. calcimimetic agents have undergone
clinical trial investigation and were published after our guideline systematic review.
However, while data on safety and efficacy were generated, no patient-level outcomes
were reported. Therefore, these trials did not impact the current recommendation.146,
147
In summary, the Work Group was divided as to whether the EVOLVE data are sufficient
to recommend cinacalcet as first-line therapy for all patients with SHPT and CKD G5D
requiring PTH lowering. One viewpoint is that the primary endpoint of the EVOLVE study
was negative. The alternative viewpoint is that secondary analyses found effects on
patient-level endpoints, while there are no positive data on mortality or patient-centered
endpoints from trials with calcitriol or other vitamin D analogs. Given the lack of
uniform consensus among the Work Group and the higher acquisition cost of cinacalcet,
it was decided to modify the 2009 recommendation to list all acceptable treatment
options in alphabetical order. The individual choice should continue to be guided
by considerations about concomitant therapies and the present calcium and phosphate
levels. In addition, the choice of dialysate calcium concentrations will impact on
serum PTH levels. Finally, it should be pointed out that parathyroidectomy remains
a valid treatment option especially in cases when PTH-lowering therapies fail, as
advocated in Recommendation 4.2.5 from the 2009 KDIGO CKD-MBD guideline.
To date, studies of cinacalcet in children are limited to case reports,
148
case series,149, 150 a single-center experience (with 28 patients with CKD G4–G5),
151
and an open-label study of a single dose in 12 children on dialysis.
152
In recognition of the unique calcium demands of the growing skeleton, PTH-lowering
therapies should be used with caution in children to avoid hypocalcemia. Future studies
are needed in children before pediatric-specific recommendations can be issued.
Research recommendations
•
The Work Group explicitly endorses the presence of clinical equipoise and the need
to conduct placebo-controlled trials with calcimimetics versus standard therapy for
the treatment of SHPT in patients with CKD G5D with emphasis on those at greatest
risk (e.g., older, with cardiovascular disease).
•
Prospective RCTs aiming at patient-centered surrogate outcomes (primary endpoints:
mortality, cardiovascular events; secondary endpoints: FGF23, LVH progression, calcification)
should be performed with the new parenteral calcimimetic compound (e.g., etelcalcitide).
•
Given the disparate effects of calcimimetic and active vitamin D therapies on FGF23
and data suggesting a clinical benefit from FGF23 reduction, RCTs evaluating the specific
reduction of FGF23 as a therapeutic endpoint should be undertaken.
Chapter 4.3: Treatment of bone with bisphosphonates, other osteoporosis medications,
and growth hormone
4.3.3: In patients with CKD G3a–G5D with biochemical abnormalities of CKD-MBD and
low BMD and/or fragility fractures, we suggest that treatment choices take into account
the magnitude and reversibility of the biochemical abnormalities and the progression
of CKD, with consideration of a bone biopsy (2D).
Rationale
Recommendation 3.2.2 now addresses the indications for a bone biopsy prior to antiresorptive
and other osteoporosis therapies. Therefore, the original Recommendation 4.3.4 from
the 2009 KDIGO CKD-MBD Guideline has been removed, and Recommendation 4.3.3 has broadened
from CKD G3a to G3b to CKD G3a to G5D. Nevertheless, when such treatment choices are
considered, their specific side effects must also be taken into account (e.g., antiresorptives
will exacerbate low bone turnover, denosumab may induce significant hypocalcemia),
and the risk of their administration must be weighed against the accuracy of the diagnosis
of the underlying bone phenotype.
Chapter 5: Evaluation and treatment of kidney transplant bone disease
5.5: In patients with CKD G1T–G5T with risk factors for osteoporosis, we suggest that
BMD testing be used to assess fracture risk if results will alter therapy (2C).
Rationale
Fracture risk is 4-fold higher in patients with end-stage kidney disease
153
compared with the general population and increases further in the early post-transplant
period.
154
A 2002 study examined the risk of hip fracture in kidney transplant recipients and
estimated the fracture rate at 3.3 events per 1000 person-years, a 34% higher risk
compared with patients receiving dialysis who were waitlisted for transplantation.
3
Bone disease in transplant recipients is complex and heterogeneous.
155
Essentially, transplant bone disease is the composite of preexisting damage to the
bone acquired during the period of renal insufficiency and damage to the bone starting
in the period of transplantation. In contrast to older studies,
156
recent cohort studies showed minimal BMD losses in the early post-transplant period,
which seem to be restricted to sites rich in cortical bone such as the distal radius.
157
A low cumulative steroid exposure along with persistent hyperparathyroidism most likely
accounts for this shift.
157
The widespread implementation of steroid minimization protocols may explain the favorable
trend in fracture risk in kidney transplant recipients observed over the last 2 decades.158,
159, 160
The 2009 KDIGO CKD-MBD Guideline
30
recommended BMD testing in the first 3 months following transplantation in patients
with an eGFR greater than 30 ml/min/1.73 m2 if they receive corticosteroids or have
risk factors for osteoporosis (Recommendation 5.5), but recommended that DXA BMD not
be performed in those with CKD G4T to G5T (Recommendation 5.7). As detailed in the
new aforementioned Recommendation 3.2.1, there is growing evidence that DXA BMD predicts
fractures across the spectrum of CKD severity, including 4 prospective cohort studies
in patients with CKD G3a to G5D10, 13 (Supplementary Tables S7–S12). To date, there
are no prospective studies addressing the ability of DXA to predict fractures in transplant
recipients. However, a retrospective cohort study conducted in 238 kidney transplant
recipients with CKD G1T to G5T examined the associations of DXA BMD with fracture
events.
161
Lumbar spine and total-hip BMD results were expressed as T-scores and categorized
as normal (T-score ≥ −1), osteopenic (T-score < −1 and > −2.5), or osteoporotic (T-score ≤ −2.5).
A total of 46 incident fractures were recorded in 53 patients. In a multivariate Cox
analysis of DXA BMD results in the total hip, osteopenia (HR: 2.7, 95% CI: 1.6–4.6)
and osteoporosis (HR: 3.5, 95% CI: 1.8–6.4) were associated with significantly increased
risk of fracture compared with normal BMD, independent of age, sex, and diabetes.
Multivariate models were not provided for the lumbar spine BMD T-score results; however,
unadjusted analyses suggested that spine BMD provided less fracture prediction compared
with total-hip BMD. Although this DXA study in kidney transplant recipients was not
eligible for the evidence-based review due to its retrospective design, the Work Group
concluded that the findings were consistent with the other studies in CKD G3a to G5D
described above.
In summary, there is growing evidence that DXA BMD predicts fractures in patients
with CKD across the spectrum, with limited data suggesting these findings extend to
transplant recipients. The revised guideline statement recommends BMD testing in transplant
recipients, as in those with CKD G3a to G5D, if the results will impact treatment
decisions.
Research recommendations
•
The research recommendations outlined for Recommendation 3.2.1 should be expanded
to include studies in kidney transplant recipients.
•
Prospective studies in patients with CKD G1T to G5T should be performed to determine
the value of BMD and bone biomarkers as predictors of fractures.
5.6: In patients in the first 12 months after kidney transplant with an estimated
glomerular filtration rate greater than approximately 30 ml/min/1.73 m
2
and low BMD, we suggest that treatment with vitamin D, calcitriol/alfacalcidol, and/or
antiresorptive agents be considered (2D).
•
We suggest that treatment choices be influenced by the presence of CKD-MBD, as indicated
by abnormal levels of calcium, phosphate, PTH, alkaline phosphatases, and 25(OH)D
(2C).
•
It is reasonable to consider a bone biopsy to guide treatment (Not Graded).
There are insufficient data to guide treatment after the first 12 months.
Rationale
The rationale for revised guideline Recommendation 3.2.2 now addresses the indications
for a bone biopsy prior to antiresorptive and other osteoporosis therapies. Therefore,
the second bullet statement above concerning bone biopsies has been modified.
Cinacalcet is not approved for the treatment of hyperparathyroidism in kidney transplant
recipients; however, it is clinically used, especially in patients with significant
hypercalcemia. While efficiently correcting hypercalcemia, cinacalcet so far has failed
to show a beneficial impact on bone mineralization in the transplant population.
162
Denosumab was recently shown to effectively increase BMD in de novo kidney transplant
recipients.
163
However, baseline BMD on average was not very low in this trial, and there was no
progressive BMD loss in the control group. Furthermore, an increased rate of urinary
tract infections was observed. In terms of safety and efficacy, an RCT comparing denosumab
and bisphosphonates in eligible patients at risk may be a reasonable future study
approach. As pointed out in the rationale for Recommendation 5.5, however, the urgency
for correcting bone mineralization in transplant recipients may diminish due to the
wide application of steroid minimization schemes.
159
Methodological approach to the 2017 KDIGO CKD-MBD guideline update
Purpose
In 2009, KDIGO developed a clinical practice guideline on the diagnosis, evaluation,
prevention, and treatment of CKD-MBD.
30
Because of the limited evidence, many of the recommendations were deliberately vague.
In October of 2013, KDIGO held a Controversies Conference to determine whether there
was sufficient new evidence to support updating any of the recommendations. Based
on the discussions at the conference, the participants opted for a “selective update”
of the guideline.
1
The purpose of this chapter is to describe the methods used to conduct the evidence
review and to develop and update the guideline recommendations.
Overview of the Process
The process of updating the guideline consisted of the following steps:
•
Convening of a Controversies Conference to determine whether sufficient new data exist
to support a reassessment of the guideline
•
Appointing a Work Group and an ERT
•
Refining the research questions
•
Developing the search strategy, inclusion/exclusion criteria, and data extraction
tables
•
Drafting the evidence matrices and evidence profiles
•
Revising the recommendations
•
Grading the quality of the evidence
•
Grading the strength of the recommendation
Controversies Conference
In October 2013, KDIGO held a Controversies Conference entitled, “CKD-MBD: Back to
the Future,” in Madrid, Spain.
1
The purpose of the conference was to determine whether there was sufficient new evidence
to support updating any of the recommendations from the 2009 KDIGO guideline on the
diagnosis, evaluation, prevention, and treatment of CKD-MBD. Seventy-four experts
in adult, pediatric, and transplant nephrology, endocrinology, cardiology, bone histomorphometry
pathology, and epidemiology attended the conference.
Four topic areas were considered: (i) vascular calcification; (ii) bone quality; (iii)
calcium and phosphate; and (iv) vitamin D and PTH. Each participant was assigned to
1 of the 4 topics based on their area of expertise. Participants identified new studies
in their topic area and answered a set of questions to determine which recommendations
required reevaluation.
1
The result was a list of recommendations to be addressed in a selected update (i.e.,
to use specific methods to update only those parts of the guideline in need of update).
There was a public review of the scope of work for the guideline.
Appointment of guideline Work Group and evidence review team
The KDIGO co-chairs appointed 2 chairs for the Guideline Work Group, who then assembled
the Work Group to be responsible for the development of the guideline. The Work Group
comprised domain experts, including individuals with expertise in adult and pediatric
nephrology, bone disease, cardiology, and nutrition. The Johns Hopkins University
in Baltimore, MD, was contracted as the ERT to provide expertise in guideline development
methodology and systematic evidence review. KDIGO support staff provided administrative
assistance and facilitated communication.
The ERT consisted of methodologists with expertise in nephrology and internal medicine,
and research associates and assistants. The ERT and the Work Group worked closely
throughout the project. In January 2015, the ERT and the Work Group Co-Chairs held
a 2-day meeting in Baltimore, MD, to discuss the guideline development and systematic
review processes and to refine the key questions.
The ERT performed systematic reviews for each of the questions conducting literature
searches, abstract and full-text screening, data extraction, risk of bias assessment,
and synthesis. The ERT provided suggestions and edits on the wording of recommendations,
and on the use of specific grades for the strength of the recommendations and the
quality of evidence. The Work Group took on the primary role of writing the recommendations
and rationale, and retained final responsibility for the content of the recommendations
and the accompanying narrative.
Refinement of the research questions
The first task was to define the overall topics and goals for the guideline. Using
the recommendations identified during the Controversies Conference, the ERT drafted
research questions and identified the population, interventions, comparison, and outcomes
(PICO elements) for each research question.
The ERT recruited a technical expert panel to review the research questions. The technical
expert panel included internal and external clinicians and researchers in nephrology
and CKD. During a conference call, the technical expert panel provided feedback on
the research questions.
The Work Group Co-Chairs and the ERT refined the research questions at the 2-day meeting
in Baltimore, MD. During this meeting decisions were also made about outcomes, including
those considered most important for decision making that would be graded (key outcomes).
The finalized research questions and outcomes are presented in Table 2.
Search strategy
The ERT searched MEDLINE and the Cochrane Central Register of Controlled Trials (CENTRAL)
for the date range of December 2006 through September 2015. The December 2006 date
provided the recommended 1-year overlap with the end of the previous search.
164
The search yield was also supplemented by articles provided by the Work Group members
through February 2017.
The search strategy included MeSH and text terms for CKD and the interventions and
markers of interest (Supplementary Appendix A) and was limited to the English language.
The ERT also reviewed the list of references that were suggested during the Controversies
Conference.
All studies that had been included in the prior guideline were rereviewed to ensure
that they met the eligibility criteria.
Inclusion and exclusion criteria
With input from the Work Group, the ERT defined the eligibility criteria a priori.
The eligibility criteria for all studies were: (i) original data published in English,
(ii) followed up at least 10 patients with CKD for at least 6 months, and (iii) addressed
1 of the research questions. The minimum mean duration of follow-up of 6 months was
chosen on the basis of clinical reasoning, accounting for the hypothetical mechanisms
of action. For treatments of interest, the proposed effects on patient-centered outcomes
require long-term exposure and typically would not be evident before several months
of follow-up. The question-specific eligibility criteria are provided in Table 3,
and the overall search yield for the guideline systematic review is summarized in
Supplementary Appendix B.
Table 3
Question-specific eligibility criteria
2009 recommendation no.
Exposure or intervention
Eligibility criteria
3.2.1, 4.3.4
Bisphosphonates, teriparatide, denosumab, or raloxifene
•
RCT with at least 10 participants per arm for the outcome of bone quality and at least
25 participants per arm for all other outcomes
•
Evaluates bone quality, bone mineral density, or fracture
3.2.2, 5.5, 5.7
Predictive value of BMD results
•
RCT with at least 25 participants per arm or a prospective cohort study with 50 participants
•
Evaluates fractures or renal osteodystrophy
4.1.1, 4.1.2
Serum phosphate or serum calcium levels
•
RCT with at least 25 participants per arm or a prospective cohort study with 50 participants
•
Evaluates mortality, GFR decline, cardiovascular or cerebrovascular events, phosphate
levels, calcium levels, bone histology, bone mineral density, bone volume, vascular
and valvular calcification imaging, hospitalizations, quality of life, kidney or kidney
graft failure, fractures, parathyroidectomy, clinical adverse events, growth, skeletal
deformities, bone accrual, or calciphylaxis or calcific uremic arteriolopathy
4.1.3
Dialysate calcium concentrations
•
RCT with at least 25 participants per arm
•
Evaluates mortality, cardiovascular or cerebrovascular events, calcium levels, bone
histology, bone mineral density, bone volume, vascular and valvular calcification
imaging, measures of GFR, hospitalizations, quality of life, kidney or kidney graft
failure, fractures, parathyroidectomy, clinical adverse events, growth, skeletal deformities,
bone accrual, or calciphylaxis or calcific uremic arteriolopathy
4.1.4, 4.1.7, 4.2.1, 4.2.2, 4.2.4
Dietary phosphate intake, phosphate-binding agents, calcium supplements, native vitamin
D, vitamin D analogs, calcitriol, or calcimimetics
•
RCT with at least 25 participants per arm
•
Evaluates mortality, cardiovascular or cerebrovascular events, GFR decline, calcium
levels, phosphate levels, parathyroid hormone levels, 25-hydroxyvitamin D or 1,25-dihydroxyvitamin
D levels, alkaline phosphatases, bone-specific alkaline phosphatase, bicarbonate,
FGF23, bone histology, bone mineral density, bone volume, vascular and valvular calcification
imaging, measures of GFR, hospitalizations, quality of life, kidney or kidney graft
failure, fractures, parathyroidectomy, clinical adverse events, growth, skeletal deformities,
bone accrual, calciphylaxis or calcific uremic arteriolopathy for any of the above
interventions, or LVH or hypercalcemia for vitamin D analogs
BMD, bone mineral density; FGF23, fibroblast growth factor 23; GFR, glomerular filtration
rate; LVH, left ventricular hypertrophy; RCT, randomized controlled trial.
Two reviewers independently screened titles and abstracts and full-text articles for
inclusion. Differences regarding inclusion were resolved through consensus adjudication.
Any study not meeting the inclusion criteria could be cited in the narrative but was
not considered part of the body of evidence for a particular recommendation.
Data extraction
The ERT modified the online supplementary tables from the prior guideline. One reviewer
abstracted data directly into the modified tables, and a second reviewer confirmed
the data abstraction. The ERT abstracted data on general study characteristics, participant
characteristics, interventions and co-interventions, and outcome measures, including
measures of variability.
Two reviewers independently assessed individual study quality using the Cochrane Collaboration’s
tool
165
for assessing risk of bias for RCTs and using the Quality in Prognosis Studies tool
166
for observational studies.
The Work Group critically reviewed draft tables, and tables were revised as appropriate.
Evidence matrices and evidence profiles
The ERT created evidence matrices for each of the key outcomes for each research question.
For each key outcome, the matrix lists the individual studies, their sample size,
follow-up duration, and the individual study quality. The ERT also drafted evidence
profiles to display the total number and overall quality of the studies addressing
each key outcome for each research question.
Revising recommendations
In June 2015, the Work Group and the ERT convened a 3-day meeting in Baltimore, MD,
to review the summary tables, evidence profiles, and evidence matrices; to decide
whether and how the recommendations should be revised; and to determine a grade that
described the quality of the overall evidence and a grade for the strength of each
recommendation.
Grading
A structured approach—modeled after Grading of Recommendations Assessment, Development,
and Evaluation (GRADE)167, 168, 169, 170, 171, 172 and facilitated by the use of evidence
profiles and evidence matrices—was used to determine a grade that described the quality
of the overall evidence and a grade for the strength of a recommendation. For each
topic, the discussion on grading of the quality of evidence was led by the ERT, and
the discussion regarding the strength of the recommendations was led by the Work Group
Chairs.
Grading the quality of evidence for each outcome
The ‘quality of a body of evidence’ refers to the extent to which our confidence in
an estimate of effect is sufficient to support a particular recommendation. Following
GRADE, the quality of a body of evidence pertaining to a particular outcome of interest
is initially categorized on the basis of study design. For questions of interventions,
the initial quality grade is “high” if the body of evidence consists of RCTs, “low”
if it consists of observational studies, or “very low” if it consists of studies of
other study designs. For questions of interventions, the Work Group graded only RCTs.
The grade for the quality of evidence for each intervention–outcome pair was then
decreased if there were serious limitations to the methodological quality of the aggregate
of studies; if there were important inconsistencies in the results across studies;
if there was uncertainty about the directness of evidence including a limited applicability
of findings to the population of interest; if the data were imprecise or sparse; or
if there was thought to be a high likelihood of bias. The final grade for the quality
of evidence for an intervention–outcome pair could be 1 of the following 4 grades:
“high,” “moderate,” “low,” or “very low” (Table 4).
Table 4
GRADE system for grading quality of evidence for an outcome
Step 1: starting grade for quality of evidence based on study design
Step 2: reduce grade
Step 3: raise grade
Final grade for quality of evidence for an outcomea
High for randomized controlled trialsModerate for quasi-randomized trialLow for observational
studyVery low for any other evidence
Study quality–1 level if serious limitations–2 levels in very serious limitationsConsistency–1
level if important inconsistencyDirectness–1 level if some uncertainty–2 levels if
major uncertaintyOther–1 level if sparse or imprecise data–1 level if high probability
of reporting bias
Strength of association+1 level is strong,b no plausible confounders, consistent and
direct evidence+2 levels if very strong,c no major threats to validity and direct
evidenceOther+1 level if evidence of a dose-response gradient+1 level if all residual
confounders would have reduced the observed effect
HighModerateLowVery low
GRADE, grading of recommendations assessment, development, and evaluation; RR, relative
risk.
a
The highest possible grade is “high” and the lowest possible grade is “very low.”
b
Strong evidence of association is defined as “significant RR of > 2 (< 0.5)” based
on consistent evidence from two or more observational studies, with no plausible confounders.
c
Very strong evidence of association is defined as “significant RR of > 5 (< 0.2)”
based on direct evidence with no major threats to validity.
Modified with permission from Uhlig K, Macleod A, Craig J, et al. Grading evidence
and recommendations for clinical practice guidelines in nephrology. A position statement
from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058–2065.
171
Grading the overall quality of evidence
The quality of the overall body of evidence was then determined on the basis of the
quality grades for all outcomes of interest, taking into account explicit judgments
about the relative importance of each outcome. The resulting 4 final categories for
the quality of overall evidence were A, B, C, and D (Table 5). This grade for overall
evidence is indicated behind the strength of recommendations. The summary of the overall
quality of evidence across all outcomes proved to be very complex. Thus, as an interim
step, the evidence profiles recorded the quality of evidence for each of 3 outcome
categories: patient-centered outcomes, other bone and vascular surrogate outcomes,
and laboratory outcomes. The overall quality of evidence was determined by the Work
Group and is based on an overall assessment of the evidence. It reflects that, for
most interventions and tests, there is no high-quality evidence for net benefit in
terms of patient-centered outcomes.
Table 5
Final grade for overall quality of evidence
Grade
Quality of evidence
Meaning
A
High
We are confident that the true effect lies close to that of the estimate of the effect.
B
Moderate
The true effect is likely to be close to the estimate of the effect, but there is
a possibility that it is substantially different.
C
Low
The true effect may be substantially different from the estimate of the effect.
D
Very low
The estimate of effect is very uncertain, and often will be far from the truth.
Assessment of the net health benefit across all important clinical outcomes
Net health benefit was determined on the basis of the anticipated balance of benefits
and harm across all clinically important outcomes. The assessment of net health benefit
by the Work Group and ERT is summarized in one of the following statements: (i) There
is net benefit from intervention when benefits outweigh harm; (ii) there is no net
benefit; (iii) there are trade-offs between benefits and harm when harm does not altogether
offset benefits but requires consideration in decision making; or (iv) uncertainty
remains regarding net benefit (Table 6).
Table 6
Balance of benefits and harms
When there was evidence to determine the balance of medical benefits and harm of an
intervention to a patient, conclusions were categorized as follows:
Net benefits
The intervention clearly does more good than harm.
Trade-offs
There are important trade-offs between the benefits and harm.
Uncertain trade-offs
It is not clear whether the intervention does more good than harm.
No net benefits
The intervention clearly does not do more good than harm.
Grading the recommendations
The “strength of a recommendation” indicates the extent to which one can be confident
that adherence to the recommendation will do more good than harm. The strength of
a recommendation is graded as Level 1 or Level 2.
173
Table 7 shows the nomenclature for grading the strength of a recommendation and the
implications of each level for patients, clinicians, and policy makers. Recommendations
can be for or against doing something. Table 8 shows that the strength of a recommendation
is determined not just by the quality of evidence, but also by other, often complex
judgments regarding the size of the net medical benefit, values and preferences, and
costs.
Table 7
Implications of the strength of a recommendation
Grade
Implications
Patients
Clinicians
Policy
Level 1:“We recommend”
Most people in your situation would want the recommended course of action, and only
a small proportion would not.
Most patients should receive the recommended course of action.
The recommendation can be evaluated as a candidate for developing a policy or a performance
measure.
Level 2:“We suggest”
The majority of people in your situation would want the recommended course of action,
but many would not.
Different choices will be appropriate for different patients. Each patient needs help
to arrive at a management decision consistent with her or his values and preferences.
The recommendation is likely to require substantial debate and involvement of stakeholders
before policy can be determined.
Table 8
Determinants of strength of recommendation
Factor
Comment
Balance between desirable and undesirable effects
The larger the difference between the desirable and undesirable effects, the more
likely a strong recommendation is warranted. The narrower the gradient, the more likely
a weak recommendation is warranted.
Quality of the evidence
The higher the quality of evidence, the more likely a strong recommendation is warranted.
Values and preferences
The more variability in values and preferences, or the more uncertainty in values
and preferences, the more likely a weak recommendation is warranted.
Costs (resource allocation)
The higher the costs of an intervention—that is, the more resources consumed—the less
likely a strong recommendation is warranted.
Ungraded statements
The Work Group felt that having a category that allows it to issue general advice
would be useful. For this purpose, the Work Group chose the category of a recommendation
that was not graded. Typically, this type of ungraded statement met the following
criteria: it provides guidance on the basis of common sense; it provides reminders
of the obvious; and it is not sufficiently specific to allow an application of evidence
to the issue, and therefore it is not based on a systematic review. Common examples
include recommendations regarding the frequency of testing, referral to specialists,
and routine medical care. The ERT and Work Group strove to minimize the use of ungraded
recommendations.
Limitations of approach
Although the literature searches were intended to be comprehensive, they were not
exhaustive. MEDLINE and Cochrane CENTRAL were the only databases searched, and the
search was limited to English language publications. Hand searches of journals were
not performed, and review articles and textbook chapters were not systematically searched.
However, Work Group members did identify additional or new studies for consideration.
Nonrandomized studies were not systematically reviewed for studies of interventions.
The ERT and Work Group resources were devoted to review of randomized trials, as these
were deemed most likely to provide data to support treatment recommendations with
higher-quality evidence.
Evidence for patient-relevant clinical outcomes was low. Usually, low-quality evidence
required a substantial use of expert judgment in deriving a recommendation from the
evidence reviewed.
Formulation and vetting of recommendations
Recommendations were drafted to be clear and actionable, and the wording also considered
the ability of concepts to be translated accurately into other languages. The final
wording of recommendations and corresponding grades for the strength of the recommendations
and the quality of evidence were voted upon by the Work Group and required a majority
to be accepted.
The process of peer review included an external review by the public to ensure widespread
input from numerous stakeholders, including patients, experts, and industry and national
organizations.
Format for chapters
Each chapter contains one or more specific recommendations. Within each recommendation,
the strength of the recommendation is indicated as level 1 or level 2, and the quality
of the overall supporting evidence is shown as A, B, C, or D. The recommendations
are followed by a section that describes the body of evidence and rationale for the
recommendations. In relevant sections, research recommendations suggest future research
to resolve current uncertainties.
Biographic and disclosure information
Markus Ketteler, MD, FERA (Work Group co-chair), is professor of medicine and currently
serves as Division Chief of Nephrology at the Klinikum Coburg in Coburg, Germany.
In 2016, he was additionally appointed as chief medical officer at this institution.
He is also chairman of the Medical Board of a large German not-for-profit dialysis
provider (KfH Kuratorium für Dialyse und Nierentransplantation e.V.). His research
focus is aimed at the understanding of the pathomechanisms involved in extraosseous
calcifications, and of phosphate and vitamin D metabolism in CKD. He has authored
more than 190 peer-reviewed publications including in The Lancet, Journal of the American
Society of Nephrology (JASN), Journal of Clinical Investigation, and Kidney International.
Dr. Ketteler has acted as local, national, or European Principal Investigator in several
clinical multicenter trials in the CKD-MBD field (e.g., SVCARB, CALMAG, IMPACT-SHPT,
PA-CL-05A and -05B, and NOPHOS). He serves on the editorial boards of nephrology journals
such as JASN and Nephrology Dialysis Transplantation (theme editor), acted as a KDIGO
Work Group member on the CKD-MBD Guideline from 2006 to 2009, and co-leads the German
Calciphylaxis Registry. Dr. Ketteler is currently council member and chairman of the
administrative office of the European Renal Association–European Dialysis and Transplant
Association (ERA-EDTA) (2012–2018). He acted as co-chair of the KDIGO Controversies
Conference on CKD-MBD, which took place in Madrid in October 2013. In 2017, he was
elected into the board of directors of the Kidney Health Initiative, representing
the ERA-EDTA for 3 years.
Consultant: Amgen, Fresenius Medical Care, Pfizer, Sanifit, Sanofi, Vifor Fresenius
Medical Care Renal Pharma
Speaker: Amgen, BMS, Medice, Pfizer, Sanofi, Vifor Fresenius Medical Care Renal Pharma
Mary B. Leonard, MD, MSCE (Work Group co-chair), is the Arline and Pete Harman Professor
and chair of the Department of Pediatrics at Stanford University School of Medicine.
She is also the Adalyn Jay Physician-in-Chief of Lucile Packard Children’s Hospital,
and the director of the Stanford Child Health Research Institute. Dr. Leonard received
her MD degree from Stanford University and subsequently completed her pediatrics internship,
residency, and nephrology fellowship at the Children’s Hospital of Philadelphia. After
completing a master’s degree in clinical epidemiology at the University of Pennsylvania
in 1997, she joined the faculty in the Departments of Pediatrics and Biostatistics
and Epidemiology. She has maintained continuous National Institutes of Health funding
for over 20 years, and her multidisciplinary research program is primarily focused
on the impact of childhood chronic diseases on growth, skeletal development, nutrition,
and physical function, with an emphasis on the detrimental effects of CKD. She co-chaired
the ISCD Pediatric Position Development Conferences in 2007 and 2013. Dr. Leonard
has served as an Associate Editor for Journal of the American Society of Nephrology
and Journal of Bone and Mineral Research. She has published over 150 peer-reviewed
manuscripts and is a member of the American Society of Clinical Investigation, American
Pediatric Society, and the Society for Pediatric Research.
Dr. Leonard declared no competing interests.
Geoffrey A. Block, MD, is a clinical nephrologist and director of research at Denver
Nephrology. He received his MD at the University of Cincinnati and completed his fellowship
in nephrology at the University of Michigan, where he was trained under the mentorship
of Dr. Friedrich Port at the United States Renal Data System. Dr. Block started a
clinical research department at Denver Nephrology in 1998, and his primary research
focus has been on clinical outcomes associated with CKD-MBD. He has published observational
reports on the risks associated with disorders of mineral metabolism and has designed,
conducted, and published numerous RCTs using a variety of interventions related to
mineral metabolism and complications of CKD. He has served as a Work Group member
on the 2009 KDIGO CKD-MBD guideline, 2 technical expert panels for Centers for Medicare
and Medicaid Services related to bone and mineral disorders, and as a member of the
steering committee for the EVOLVE trial. He serves as a reviewer for Clinical Journal
of the American Society of Nephrology, Journal of the American Society of Nephrology,
American Journal of Kidney Diseases, and Kidney International and was associate editor
of Nephron-Clinical Practice.
Consultant: Ardelyx, Amgen, AstraZeneca, Celgene, Keryx, Kirin, Ono Pharmaceutical,
OPKO
Grant/research support: Keryx*
Speaker: OPKO
Development of educational materials: Amgen, Keryx, OPKO
Stock/stock options: Ardelyx
Other: medical director, DaVita
*Monies paid to institution.
Pieter Evenepoel, MD, PhD, FERA, is head of the dialysis unit, division of nephrology,
at the University Hospitals Leuven. Dr. Evenepoel completed his medical training at
the Catholic University of Leuven, Belgium, in 1992, where he also received his PhD
for research on protein assimilation and fermentation in 1997. In 2000, he joined
the University Hospitals Leuven, where he gained his certification as Specialist in
Internal Medicine and Nephrology. Dr. Evenepoel has maintained an active research
interest in mainly clinical aspects of CKD-MBD, as exemplified by numerous original
articles, review papers, and commentaries in this field. He is currently a board member
of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA)
working group on CKD-MBD. His research interests span areas including uremic toxins,
nutrition, and anticoagulation, and he has authored over 200 publications. He serves
presently as associate editor of Nephrology Dialysis Transplantation and editorial
board member for Kidney International. He is also an Ordinary Council Member of the
ERA-EDTA.
Consultant: Amgen, Vifor Fresenius Medical Care Renal Pharma
Grant/research support: Amgen, TECOmedical
Speaker: Amgen, Vifor Fresenius Medical Care Renal Pharma
Miscellaneous travel and meeting expenses unrelated to above: Amgen, Shire
Masafumi Fukagawa, MD, PhD, FASN, received his MD in 1983 from the University of Tokyo
School of Medicine, Tokyo, Japan. Following a subspecialty training and PhD program
in Tokyo, he was a research fellow at Vanderbilt University School of Medicine, Nashville,
TN, until 1995. From 2000 to 2009, he was associate professor and director of the
Division of Nephrology and Kidney Center at Kobe University School of Medicine, Kobe,
Japan, and he later moved to Tokai University School of Medicine, Isehara, Japan,
as professor of medicine and the director of the Division of Nephrology, Endocrinology,
and Metabolism. He was international associate editor of Clinical Journal of the American
Society of Nephrology (CJASN) (2005–2010) and currently serves as associate editor
for Journal of Bone and Mineral Metabolism. He is an editorial board member for Kidney
International, American Journal of Kidney Diseases, CJASN, Nephrology Dialysis Transplantation,
and Clinical and Experimental Nephrology. In addition, he served as a Work Group member
for the 2009 KDIGO CKD-MBD guideline and also chaired the committee for the new version
of the Japanese clinical guideline on CKD-MBD by the Japanese Society for Dialysis
Therapy.
Consultant: Kyowa Hakko Kirin, Ono Pharmaceutical, Torii
Grant/research support: Bayer Japan*, Kyowa Hakko Kirin*
Speaker: Bayer Japan, Kyowa Hakko Kirin, Torii
Manuscript preparation: Bayer Japan, Kyowa Hakko Kirin
*Monies paid to institution.
Charles A. Herzog, MD, FACC, FAHA, is professor of medicine at University of Minnesota
and a cardiologist at Hennepin County Medical Center (HCMC) for 32 years. He founded
the program in interventional cardiology at HCMC and served as cardiac catheterization
laboratory director from 1985 to 1991, and cardiac ultrasound laboratory director
from 1997 to 2012. He was director of the United States Renal Data System Cardiovascular
Special Studies Center from 1999 to 2014. Dr. Herzog participated in the development
of the National Kidney Foundation’s K/DOQI Clinical Practice Guidelines for Cardiovascular
Disease in Dialysis Patients and KDIGO Clinical Practice Guideline on Acute Kidney
Injury. He also co-chaired the 2010 KDIGO Controversies Conference, “Cardiovascular
Disease in CKD: What is it and What Can We Do About It?” and is a co-chair of the
ongoing KDIGO Kidney, Heart, and Vascular Conference Series. Dr. Herzog was an executive
committee member of the EVOLVE trial, and presently he is chairing the renal committee
of the ISCHEMIA-CKD trial and is co-principal investigator of the WED-HED (Wearable
Cardioverter Defibrillator in Hemodialysis Patients) study. He has over 220 published
papers and has served on the editorial boards of the American Heart Journal, Journal
of Nephrology, Clinical Journal of the American Society of Nephrology, and liaison
editor for Nephrology Dialysis Transplantation. His special interests include cardiac
disease and CKD, and echocardiography.
Consultant: AbbVie, Fibrogen, Relypsa, Sanifit, ZS Pharma
Employment: Hennepin County Medical Center, Chronic Disease Research Group
Grants/research support: Amgen*, Zoll*
*Monies paid to institution.
Linda McCann, RD, CSR, has been a nephrology dietitian for over 43 years, focused
on quality patient care, professional management, and electronic applications for
kidney disease and nutrition. She is currently a nephrology nutrition consultant and
speaker. Ms. McCann was a member of the original KDOQI and KDIGO advisory committees
as well as the KDOQI and KDIGO (original and update) Work Groups that developed and
published clinical practice guidelines and recommendations for bone and mineral abnormalities
in CKD. She is the author of the popular National Kidney Foundation (NKF) publication,
Pocket Guide to Nutrition Assessment of the Patient with Kidney Disease, currently
in its fifth edition. She has authored book chapters and published multiple peer-reviewed
papers in the area of nephrology nutrition. She has a long history of mentoring other
professionals, driving clinical excellence, and is a dedicated patient advocate. Ms.
McCann has also received numerous awards including: Recognized Renal Dietitian (Council
on Renal Nutrition), Multiple Outstanding Service Awards (NKF), Award of Distinguished
Service (NKF Northern California), Champion of Hope (NKF Northern California), Joel
D. Kopple Award (NKF National), San Jose Business Journal 100 Women of Influence 2012,
and the American Association of Kidney Patients Medal of Excellence.
Consultant: Amgen, Relypsa, Sanofi
Speaker: Amgen, Relypsa, Sanofi
Development of educational presentations: Amgen, Relypsa, Sanofi
Sharon M. Moe, MD, is the director of the Division of Nephrology and Stuart A. Kleit
Professor of Medicine for the Indiana University School of Medicine. She received
her medical degree from the University of Illinois–College of Medicine at Chicago
in 1989 and completed her residency in Internal Medicine at Loyola University Medical
Center in Maywood, IL. Her research and clinical fellowships were completed in nephrology
at the University of Chicago in Illinois. Dr. Moe has been a faculty member at Indiana
University since 1992 and is currently division director for nephrology in the Department
of Medicine at Indiana University School of Medicine and section chief for nephrology
at the Roudebush VA Medical Center. She has also served as the associate dean for
Research Support in the Indiana University School of Medicine and the vice-chair for
research in the Department of Medicine.
Dr. Moe is the principal investigator for several ongoing basic and clinical research
studies in the field of CKD-MBD, including studies on vascular calcification, mineral
metabolism, and bone metabolism in kidney disease. Her research is funded by the Veterans
Affairs Department, the National Institutes of Health, foundations, and pharmaceutical
companies. She has authored over 200 scientific manuscripts, teaching manuscripts,
and textbook chapters. Dr. Moe served on the National Kidney Foundation's (NKF) KDOQI
Bone and Mineral Metabolism Clinical Practice Guideline Work Group in 2003 and was
co-chair of the international KDIGO CKD-MBD guideline released in 2009.
Dr. Moe’s key honors include: election to the American Society for Clinical Research
in 2005; the NKF Garabed Eknoyan Award for exceptional contributions to key initiatives
such as KDOQI in 2009; councilor to the American Heart Association Kidney Council
(2002–2004); International Society of Nephrology (2005–2007); councilor for the American
Society of Nephrology (2008–2015) and president of the American Society of Nephrology
(2013-2014); and election to the Association of American Physicians in 2017.
Consultant: Lilly, Ultragenyx
Grants/research support: NIH, Veterans Administration
Speaker: Sanofi, University of Kansas
Stock/stock options: Lilly
Rukshana Shroff, MD, FRCPCH, PhD, is a consultant in pediatric nephrology at Great
Ormond Street Hospital for Children in London, UK, and holds an academic position
(reader) in nephrology at University College London. Her research focuses on cardiovascular
disease in childhood CKD, including laboratory work, clinical research studies, and
clinical trials. She is the principal investigator on a multicenter study comparing
long-term outcomes of conventional hemodialysis and hemodiafiltration in children.
She currently holds a prestigious senior fellowship from the National Institute for
Health Research to continue research into mineral dysregulation in CKD. She has published
more than 130 original articles, reviews, and book chapters in the fields of nephrology
and dialysis. Dr. Shroff has also served on 2 guideline committees for the National
Institute for Health and Care Excellence. She is on the council for the European Society
for Pediatric Nephrology. She is presently an associate editor for Pediatric Nephrology
and serves on the editorial board of Clinical Journal of the American Society of Nephrology.
Consultant: AstraZeneca
Grant/research support: Fresenius Medical Care*
Speaker: Amgen, Fresenius Medical Care
*Monies paid to institution.
Marcello A. Tonelli, MD, SM, FRCPC, is senior associate dean (clinical research) at
the Cumming School of Medicine and associate vice president (health research) at the
University of Calgary. He received an MD from the University of Western Ontario, specialist
certification in nephrology (FRCPC) at Dalhousie University, an SM in epidemiology
from Harvard University, and an MSc in health policy from Imperial College London.
He is a nephrologist and professor at the University of Calgary.
Dr. Tonelli is the past president of the Canadian Society of Nephrology, a past councilor
of the International Society of Nephrology, and the chair of the International Society
of Nephrology Research Committee. He is a fellow of the Canadian Academy of Health
Sciences, and a member of the American Society for Clinical Investigation. Dr. Tonelli
is the chair of the Canadian Task Force for Preventive Health Care, a national panel
of experts that makes recommendations about preventive health services to Canada’s
36,000 family physicians.
Dr. Tonelli was the recipient of the 2013 United States National Kidney Foundation
Medal for Distinguished Service and also the 2013 Kidney Foundation of Canada Medal
for Research Excellence.
Dr. Tonelli declared no competing interests.
Nigel D. Toussaint, MBBS, FRACP, PhD, is the deputy director of nephrology at Melbourne
Health and a clinical associate professor within the Department of Medicine at the
University of Melbourne, Australia. Dr. Toussaint completed his nephrology training
in Melbourne in 2005 and completed his PhD studies at Monash University in 2009, undertaking
clinical research in the area of vascular calcification and cardiovascular risk in
patients with CKD. He has also completed a graduate diploma in clinical epidemiology
(Monash University, 2007), and a National Health and Medical Research Council National
Institute of Clinical Studies Fellowship (2011) in the area of implementation research.
He is a member of the Editorial Board for Nephrology and is currently a member of
council for the Australian and New Zealand Society of Nephrology.
Dr. Toussaint practices nephrology at The Royal Melbourne Hospital, where he is also
the lead physician for clinical research within the Nephrology Department. His current
research involves clinical epidemiology and clinical trials, as well as translational
research, in the areas of CKD-MBD biomarkers, vascular calcification, and renal osteodystrophy.
He has been an awardee of the Royal Australasian College of Physicians Jacquot Research
Establishment Award and is a member of the Scientific Committee for the Australasian
Kidney Trials Network and the steering committee for the Australia and New Zealand
Dialysis and Transplant Registry.
Advisory board: Amgen, Sanofi, Shire
Consultant: Amgen, Sanofi, Shire
Grants/research support: Amgen*, Shire*
Speaker: Amgen, Sanofi, Shire
*Monies paid to institution.
Marc G. Vervloet, MD, PhD, FERA, is a nephrologist, associate professor of nephrology,
and director of the nephrology research program and senior consultant at the Intensive
Care Medicine and Vascular Medicine, VU University Medical Center, Amsterdam, Netherlands.
He is program leader at the Institute of Cardiovascular Research VU (ICaR-VU), secretary
of the CKD-MBD working group of the European Renal Association–European Dialysis and
Transplant Association, and a member of the scientific committee of the Dutch Kidney
Foundation. Dr. Vervloet obtained his medical degree in 1989, and graduated as internist
in 1997 and as nephrologist in 1999. His current research interests encompass research
on the deranged bone and metabolism in CKD. Dr. Vervloet currently heads the hemodialysis
unit at his hospital, where he performs instructional duties to medical students,
residents, and nephrology fellows, and guides several PhD students. He has gained
numerous research grants, mainly covering topics related to CKD-MBD, in particular
on the role of FGF23 and Klotho, and the clinical use of calcimimetic therapy. In
addition, his laboratory research comprises several animal models of CKD and vitamin
D deficiency, examining mainly cardiovascular endpoints as assessed by imaging and functional
testing in vivo.
Advisory board: Amgen, Fresenius Medical Care
Consultant: Amgen, Fresenius Medical Care, Otsuka
Grants/research support: AbbVie*, Fresenius Medical Care*, Sanofi*, Shire*
Speaker: Amgen, Baxter
*Monies paid to institution.
KDIGO Chairs
David C. Wheeler, MD, FRCP, is professor of kidney medicine at University College
London, UK, and honorary consultant nephrologist at the Royal Free London NHS Foundation
Trust. He is a clinician scientist with an interest in the complications of CKD, specifically
those that increase the burden of cardiovascular disease and/or accelerate progression
of kidney failure. He has participated in the design, roll-out, and monitoring of
several large-scale clinical trials. He was a member of the steering committee of
the Study of Heart and Renal Protection (SHARP) and the EValuation Of Cinacalcet HCl
Therapy to Lower CardioVascular Events (EVOLVE). He currently sits on the steering
committee of Canaglifozin and Renal Events in Diabetes with Established Nephropathy
Clinical Evaluation (CREDENCE), acting as UK principal investigator for this study.
He is clinical lead for Division 2 of the North Thames Clinical Research Network and
heads a team of eight clinical trial nurses and practitioners at the Centre for Nephrology,
Royal Free Hospital in London. He is past president of the UK Renal Association and
past chair of the UK Renal Registry. His other responsibilities include serving as
associate editor of Nephrology Dialysis Transplantation and member of the editorial
board of Journal of the American Society of Nephrology.
Consultant: Akebia, Alberta Innovates Health Solutions, Amgen, AstraZeneca, Bio Nano
Consulting, Boehringer Ingelheim, Bristol-Myers Squibb, Fresenius, GSK, Janssen*,
Otsuka, UCB Celltech, Vifor
Speaker: Amgen, Fresenius Medical Care, Janssen, Vifor Fresenius Medical Care Renal
Pharma, ZS Pharma
*Monies paid to institution.
Wolfgang C. Winkelmayer, MD, MPH, ScD, is the Gordon A. Cain Chair of Nephrology and
professor of medicine at Baylor College of Medicine in Houston, TX. Dr. Winkelmayer
received his medical degree (1990) from the University of Vienna, Austria, and later
earned a Master of Public Health degree in health care management (1999) and a Doctor
of Science degree in health policy (2001) from Harvard University. He then spent 8
years on the faculty of Brigham and Women’s Hospital and Harvard Medical School, where
he established himself as a prolific investigator and leader in the discipline of
comparative-effectiveness research as it pertains to patients with kidney disease.
From 2009 to 2014, he was the director of clinical research in the Division of Nephrology
at Stanford University School of Medicine, Palo Alto, CA. He assumed his current position
as chief of nephrology at Baylor College of Medicine in September 2014. His main areas
of research interest include comparative effectiveness and safety research of treatment
strategies in anemia as well as of various interventions for cardiovascular disease
in patients with kidney disease. His clinical passion lies in providing quality kidney
care to the predominantly disadvantaged and un(der)insured population in the public
safety net health system of Harris County, TX. Dr. Winkelmayer has authored over 270
peer-reviewed publications, and he has a particular interest in medical publishing.
He currently serves as an associate editor for The Journal of the American Medical
Association, was a co-editor of the American Journal of Kidney Diseases from 2007
to 2016, and has been appointed to several other editorial boards of leading nephrology
and epidemiology journals. He also volunteers his time toward important initiatives
of the American Society of Nephrology (e.g., public policy board). He joined KDIGO
volunteer leadership as an executive committee member in 2015 and has served as its
co-chair since 2016.
Advisory board: Akebia, AMAG Pharmaceuticals, Amgen, AstraZeneca, Bayer, Daichi Sankyo,
Medtronic, Relypsa, Vifor Fresensius Medical Care Renal Pharma
Consultant: Akebia, AMAG Pharmaceuticals, Amgen, AstraZeneca, Bayer, Daichi Sankyo,
Medtronic, Relypsa, Vifor Fresensius Medical Care Renal Pharma
Evidence review team
Karen A. Robinson, PhD, is associate professor of medicine, epidemiology and health
policy & management, and director of the Evidence-Based Practice Center at Johns Hopkins
University, serving as the project director. She provided methodological expertise
in the conduct of the systematic review and guideline development processes, and oversaw
and participated in all aspects of the project, including topic refinement, abstract
and full-text screening, data extraction, study assessment, evidence grading, and
recommendation formulation.
Dr. Robinson declared no competing interests.
Casey M. Rebholz, PhD, MPH, MS, is assistant professor of epidemiology at Johns Hopkins
Bloomberg School of Public Health and Core Faculty at the Welch Center for Prevention,
Epidemiology, and Clinical Research. She guided the team through all phases of the
project, including refining the questions, conducting literature searches, screening
abstracts and full-text articles, abstracting data, drafting and finalizing the evidence
tables, and synthesizing the results.
Dr. Rebholz declared no competing interests.
Lisa M. Wilson, ScM, is a research associate at the Johns Hopkins University Bloomberg
School of Public Health. As the project coordinator for the evidence review team,
Ms. Wilson managed and participated in all phases of the project, including conducting
literature searches, screening abstracts and full-text articles, abstracting data,
drafting and finalizing the evidence tables, and synthesizing the results.
Ms. Wilson declared no competing interests.
Ermias Jirru, MD, MPH, is currently an internal medicine resident at Mount Sinai St.
Luke’s and Mount Sinai West. He completed his MPH at the Johns Hopkins University
Bloomberg School of Public Health. For this project, he participated in screening
abstracts and full-text articles, and abstracting data.
Dr. Jirru declared no competing interests.
Marisa Chi Liu, MD, MPH, is currently a resident physician at University of California,
Irvine, in obstetrics and gynecology. She completed her MPH at Johns Hopkins University
Bloomberg School of Public Health and graduated from the University of Vermont College
of Medicine. For this project, she participated in screening abstracts and articles,
and abstracting data.
Dr. Liu declared no competing interests.
Jessica Gayleard, BS, is a research assistant within the Johns Hopkins University
Evidence-Based Practice Center. She participated in all phases of the project, including
conducting literature searches, screening abstracts and full-text articles, abstracting
data, and drafting and finalizing the evidence tables.
Ms. Gayleard declared no competing interests.
Allen Zhang, BS, is a research data analyst at the Johns Hopkins University Evidence-Based
Practice Center. He has a degree in microbiology from the Virginia Polytechnic Institute
and University. Mr. Zhang participated in the systematic review development, including
search string creation, screening, data cleaning, data management, and writing. In
addition, he supplied the necessary statistical analysis, including meta-analyses
and meta-regression calculations.
Mr. Zhang declared no competing interests.
Acknowledgments
A special debt of gratitude is owed to the KDIGO co-chairs, David Wheeler and Wolfgang
Winkelmayer, for their invaluable guidance throughout the development of this guideline.
In particular, we thank Karen Robinson and her ERT members for their substantial contribution
to the rigorous assessment of the available evidence. We are also especially grateful
to the Work Group members for their expertise throughout the entire process of literature
review, data extraction, meeting participation, the critical writing and editing of
the statements and rationale, which made the publication of this guideline possible.
The generous gift of their time and dedication is greatly appreciated. Finally, and
on behalf of the Work Group, we gratefully acknowledge the careful assessment of the
draft guideline by external reviewers. The Work Group considered all of the valuable
comments made, and where appropriate, suggested changes were incorporated into the
final publication. The following individuals provided feedback during the public review
of the draft guideline:
Patricia Abreu, Adama Lengani, Kamal Ahmed, Bülent Altun, Luis Felipe Alva, Rui Alves,
Pablo Amair, Alessandro Amore, Andrea Angioi, Mustafa Arici, Mariano Arriola, Rommel
Bataclan, Ezequiel Bellorin-Font, Deborah Benner, Mohammed Benyahia, Patrick Biggar,
Charles Bishop, Boris Bogov, Jordi Bover, Laura Brereton, Philippe Brunet, Rafael
Burgos-Calderon, Stephen Carrithers, Sue Cary, Rolando Claure-Del Granado, Adrian
Covic, Mario Cozzolino, Andrew Crannage, John Cunningham, Pierre Delanaye, Nida Dinçel,
Tilman B. Drüeke, Nordin Eezsafryna Azalin, Grahame J. Elder, Madgy ElSharkawy, Joyce
Ezaki-Yamaguchi, Toshiro Fujita, Alvaro Garcia, Carlo Francisco Gochuico, Heong Keong
Goh, Hai An Ha Phan, Takayuki Hamano, Ditte Hansen, Li Hao, Eero Honkanen, Alastair
Hutchison, Atul Ingale, Joachim H. Ix, Faical Jarraya, Chandra Mauli Jha, Kamyar Kalantar-Zadeh,
Arif Khwaja, Csaba P. Kovesdy, Holly Kramer, Craig B. Langman, Kevin V. Lemley, Edgar
V. Lerma, Nathan W. Levin, Maria Jesus Lloret, José António Lopes, Franklin W. Maddux,
Francesca Mallamaci, Sandro Mazzaferro, Peter A. McCullough, Donald A. Molony, Sameh
Morgan, Eugen Mota, Ricardo Mouzo, Lavinia Negrea, Armando Negri, Michal Nowicki,
Tom Nusbickel, Basma Osman, Susan M. Ott, Antonino Paglialunga, Saime Paydas, Adriana
Peñalba, Gerson Marques Pereira Junior, Eduardo Perez, Ligia Petrica, Friedrich K.
Port, Pradeep Kumar Rai, Dwarakanathan Ranganathan, Nicolas Roberto Robles, Cibele
Rodrigues, Hector Rodriguez, Guillermo Rosa Diez, Ibrahim Saig, Deepak Sharma, Laura
Sola, David M. Spiegel, Kyriaki Stamatelou, Ekamol Tantisattamo, Mihály Tapolyai,
Francesca Tentori, Katrin Uhlig, Harun Ur Rashid, Pablo Ureña Torres, Keth Vuthy,
Angela Yee-Moon Wang, Talia Weinstein, Jane Wheeler, Janie Xiong, and Xueqing Yu.
Participation in the review does not necessarily constitute endorsement of the content
of this report by the above individuals, or the organization or institution they represent.
Markus Ketteler, MD, FERA
Mary B. Leonard, MD, MSCE
Work Group Co-chairs